

PCT / IB 04 / 04426

11 APR 2005

**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE**

34, chemin des Colombettes, Case postale 18, CH-1211 Genève 20 (Suisse)  
Téléphone: (41 22) 338 91 11 - e-mail: wipo.mail @ wipo.int. - Fac-similé: (41 22) 733 54 28

**PATENT COOPERATION TREATY (PCT)  
TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)**

**CERTIFIED COPY OF THE INTERNATIONAL APPLICATION AS FILED  
AND OF ANY CORRECTIONS THERETO**

**COPIE CERTIFIÉE CONFORME DE LA DEMANDE INTERNATIONALE, TELLE QU'ELLE  
A ÉTÉ DÉPOSÉE, AINSI QUE DE TOUTES CORRECTIONS Y RELATIVES**



International Application No. } PCT/IB 03 / 06435  
Demande internationale n° }

International Filing Date } 18 DECEMBER 2003  
Date du dépôt international } ( 18.12.03 )

Geneva/Genève, 11 APRIL 2005  
( 11.04.05 )

**International Bureau of the  
World Intellectual Property Organization (WIPO)**

**Bureau International de l'Organisation Mondiale  
de la Propriété Intellectuelle (OMPI)**



J.-L. Baron

Head, PCT Receiving Office Section  
Chef de la section "office récepteur du PCT"

**BEST AVAILABLE COPY**

## PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

PCT/IB 03 / 0 6 4 3 5	
International Application No.	
18 DECEMBER 2003 (18.12.03)	
International Filing Date	
INTERNATIONAL BUREAU OF WIPO	
Name of receiving Office and "PCT International Application"	
Applicant's or agent's file reference (if desired) (12 characters maximum)	BGI-160PC

<b>Box No. I TITLE OF INVENTION</b>	
METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION	
<b>Box No. II APPLICANT</b> <input type="checkbox"/> This person is also inventor	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	
BASF AKTIENGESELLSCHAFT ZDZ/G D-67056 Ludwigshafen Germany	
Telephone No.	
Facsimile No.	
Teleprinter No.	
Applicant's registration No. with the Office	
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<b>Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)</b>	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	
UNIVERSITY OF SAARBRÜCKEN Postfach 151150 66041 Saarbrücken Germany	
This person is: <input checked="" type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)	
Applicant's registration No. with the Office	
State (i.e. country) of nationality: DE	State (i.e. country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on a continuation sheet.	
<b>Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE</b>	
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: <input type="checkbox"/> agent <input checked="" type="checkbox"/> common representative	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	
c/o HANLEY, Elizabeth A. BASF AKTIENGESELLSCHAFT Lahive & Cockfield, LLP 28 State Street Boston, Massachusetts 02109 United States of America	
Telephone No. (617) 227-7400	
Facsimile No. (617) 742-4214	
Teleprinter No.	
Agent's registration No. with the Office 33,505	
<input checked="" type="checkbox"/> Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.	

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

<b>PCT</b>  <b>REQUEST</b>		For receiving Office use only <b>PCT/IB 03 / 06435</b> International Application No. <b>18 DECEMBER 2003</b> International Filing Date <b>INTERNATIONAL BUREAU OF WIPO</b> Name: <b>PCT International Application</b> Applicant's or agent's file reference (if desired) (12 characters maximum) <b>BGI-160PC</b>	
<b>Box No. I TITLE OF INVENTION</b> METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION			
<b>Box No. II APPLICANT</b>		<input type="checkbox"/> This person is also inventor	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)  BASF AKTIENGESELLSCHAFT ZDZ/G D-67056 Ludwigshafen Germany		Telephone No.  Facsimile No.  Teleprinter No.  Applicant's registration No. with the Office	
State (that is, country) of nationality: DE		State (that is, country) of residence: DE	
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box			
<b>Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)</b>			
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)  UNIVERSITY OF SAARBRÜCKEN		This person is: <input checked="" type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)  Applicant's registration No. with the Office	
State (i.e. country) of nationality:		State (i.e. country) of residence:	
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box			
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on a continuation sheet.			
<b>Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE</b>			
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:		<input checked="" type="checkbox"/> agent <input type="checkbox"/> common representative	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)  HANLEY, Elizabeth A. Lahive & Cockfield, LLP 28 State Street Boston, Massachusetts 02109 United States of America		Telephone No. (617) 227-7400 Facsimile No. (617) 742-4214 Teleprinter No. Agent's registration No. with the Office 33,505	
<input checked="" type="checkbox"/> Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.			

REPLACED

(23.07.04)

Sheet No. 2 of 7

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ZELDER, Oskar  
Rossmarktstr. 27  
67346 Speyer  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KLOPPROGGE, Corinna  
Diemersteinstrasse 3  
67056 Ludwigshafen  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SCHRÖDER, Hartwig  
Goethestr. 5  
69226 Nussloch  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HAEFNER, Stefan  
Luipoldstrasse 11  
67063 Ludwigshafen  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on another continuation sheet.

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ZELDER, Oskar  
Rossmarktstr. 27  
67346 Speyer  
Germany

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KLOPPROGGE, Corinna  
Diemersteinstrasse 3  
67056 Ludwigshafen  
Germany

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SCHRÖDER, Hartwig  
Goethestr. 5  
69226 Nussloch  
Germany

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HAEFNER, Stefan  
Luipoldstrasse 11  
67063 Ludwigshafen  
Germany

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on another continuation sheet.

(23.07.04)

Sheet No. 3 of 7

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)

KRÖGER, Burkhard  
Im Waldhof 1  
67117 Limburgerhof  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KIEFER, Patrick  
AM Homburg 5G  
66123 Saarbrücken  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HEINZLE, Elmar  
Senator-Richard-Becher-Straße 48  
66123 Saarbücken  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WITTMANN, Christoph  
Am Kalkofen 13  
66127 Saarbücken  
Germany

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Sheet No. 3 of 7

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)

KRÖGER, Burkhard  
Im Waldhof 1  
67117 Limburgerhof  
Germany

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DEState (that is, country) of residence:  
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KIEFER, Patrick

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HEINZLE, Elmar

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WITTMANN, Christoph

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
DE

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No. V DESIGNATION OF STATES Mark the applicable check-boxes; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

## Regional Patent

- ☒ AP ARIPO Patent: BW Botswana, GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT .....
- ☒ EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT .....
- ☒ EP European Patent: AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, HU Hungary, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, RO Romania, SE Sweden, SI Slovenia, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT .....
- ☒ OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT .....

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |   |  |   |
|---|--|---|
| <input checked="" type="checkbox"/> AE United Arab Emirates .....               | <input checked="" type="checkbox"/> HR Croatia .....                                   | <input checked="" type="checkbox"/> OM Oman .....                             |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda .....                | <input checked="" type="checkbox"/> HU Hungary .....                                   | <input checked="" type="checkbox"/> PG Papua New Guinea .....                 |
| <input checked="" type="checkbox"/> AL Albania .....                            | <input checked="" type="checkbox"/> ID Indonesia .....                                 | <input checked="" type="checkbox"/> PH Philippines .....                      |
| <input checked="" type="checkbox"/> AM Armenia .....                            | <input checked="" type="checkbox"/> IL Israel .....                                    | <input checked="" type="checkbox"/> PL Poland .....                           |
| <input checked="" type="checkbox"/> AT Austria .....                            | <input checked="" type="checkbox"/> IN India .....                                     | <input checked="" type="checkbox"/> PT Portugal .....                         |
| <input checked="" type="checkbox"/> AU Australia .....                          | <input checked="" type="checkbox"/> IS Iceland .....                                   | <input checked="" type="checkbox"/> RO Romania .....                          |
| <input checked="" type="checkbox"/> AZ Azerbaijan .....                         | <input checked="" type="checkbox"/> JP Japan .....                                     | <input checked="" type="checkbox"/> RU Russian Federation .....               |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina .....             | <input checked="" type="checkbox"/> KE Kenya .....                                     | <input checked="" type="checkbox"/> SC Seychelles .....                       |
| <input checked="" type="checkbox"/> BB Barbados .....                           | <input checked="" type="checkbox"/> KG Kyrgyzstan .....                                | <input checked="" type="checkbox"/> SD Sudan .....                            |
| <input checked="" type="checkbox"/> BG Bulgaria .....                           | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea .....     | <input checked="" type="checkbox"/> SE Sweden .....                           |
| <input checked="" type="checkbox"/> BR Brazil .....                             | <input checked="" type="checkbox"/> KR Republic of Korea .....                         | <input checked="" type="checkbox"/> SG Singapore .....                        |
| <input checked="" type="checkbox"/> BY Belarus .....                            | <input checked="" type="checkbox"/> KZ Kazakhstan .....                                | <input checked="" type="checkbox"/> SK Slovakia .....                         |
| <input checked="" type="checkbox"/> BZ Belize .....                             | <input checked="" type="checkbox"/> LC Saint Lucia .....                               | <input checked="" type="checkbox"/> SL Sierra Leone .....                     |
| <input checked="" type="checkbox"/> CA Canada .....                             | <input checked="" type="checkbox"/> LK Sri Lanka .....                                 | <input checked="" type="checkbox"/> SY Syrian Arab Republic .....             |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein ..... | <input checked="" type="checkbox"/> LR Liberia .....                                   | <input checked="" type="checkbox"/> TJ Tajikistan .....                       |
| <input checked="" type="checkbox"/> CN China .....                              | <input checked="" type="checkbox"/> LS Lesotho .....                                   | <input checked="" type="checkbox"/> TM Turkmenistan .....                     |
| <input checked="" type="checkbox"/> CO Columbia .....                           | <input checked="" type="checkbox"/> LT Lithuania .....                                 | <input checked="" type="checkbox"/> TN Tunisia .....                          |
| <input checked="" type="checkbox"/> CR Costa Rica .....                         | <input checked="" type="checkbox"/> LU Luxembourg .....                                | <input checked="" type="checkbox"/> TR Turkey .....                           |
| <input checked="" type="checkbox"/> CU Cuba .....                               | <input checked="" type="checkbox"/> LV Latvia .....                                    | <input checked="" type="checkbox"/> TT Trinidad and Tobago .....              |
| <input checked="" type="checkbox"/> CZ Czech Republic .....                     | <input checked="" type="checkbox"/> MA Morocco .....                                   | <input checked="" type="checkbox"/> TZ United Republic of Tanzania .....      |
| <input checked="" type="checkbox"/> DE Germany .....                            | <input checked="" type="checkbox"/> MD Republic of Moldova .....                       | <input checked="" type="checkbox"/> UA Ukraine .....                          |
| <input checked="" type="checkbox"/> DK Denmark .....                            | <input checked="" type="checkbox"/> MG Madagascar .....                                | <input checked="" type="checkbox"/> UG Uganda .....                           |
| <input checked="" type="checkbox"/> DM Dominica .....                           | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia ..... | <input checked="" type="checkbox"/> US United States of America .....         |
| <input checked="" type="checkbox"/> DZ Algeria .....                            | <input checked="" type="checkbox"/> MN Mongolia .....                                  | <input checked="" type="checkbox"/> UZ Uzbekistan .....                       |
| <input checked="" type="checkbox"/> EE Estonia .....                            | <input checked="" type="checkbox"/> MW Malawi .....                                    | <input checked="" type="checkbox"/> VC Saint Vincent and the Grenadines ..... |
| <input checked="" type="checkbox"/> ES Spain .....                              | <input checked="" type="checkbox"/> MX Mexico .....                                    | <input checked="" type="checkbox"/> VN Viet Nam .....                         |
| <input checked="" type="checkbox"/> FI Finland .....                            | <input checked="" type="checkbox"/> MZ Mozambique .....                                | <input checked="" type="checkbox"/> YU Serbia and Montenegro .....            |
| <input checked="" type="checkbox"/> GB United Kingdom .....                     | <input checked="" type="checkbox"/> NI Nicaragua .....                                 | <input checked="" type="checkbox"/> ZA South Africa .....                     |
| <input checked="" type="checkbox"/> GD Grenada .....                            | <input checked="" type="checkbox"/> NO Norway .....                                    | <input checked="" type="checkbox"/> ZM Zambia .....                           |
| <input checked="" type="checkbox"/> GE Georgia .....                            | <input checked="" type="checkbox"/> NZ New Zealand .....                               | <input checked="" type="checkbox"/> ZW Zimbabwe .....                         |
| <input checked="" type="checkbox"/> GH Ghana .....                              |  |   |
| <input checked="" type="checkbox"/> GM Gambia .....                             |  |   |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

- ☒ EG Egypt .....
- ☒ BW Botswana .....

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)



**Supplemental Box** *If the Supplemental Box is not used, this sheet should not be included in the request.*

- I. *If, in any of the Boxes except Boxes Nos. VIII(i) to (v) for which a special continuation box is provided, the space is insufficient to furnish all the information: in such case, write "Continuation of box No. ..." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:*
  - (i) *if more than two persons are to be indicated as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;*
  - (ii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;*
  - (iii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;*
  - (iv) *if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box IV;*
  - (v) *if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;*
  - (vi) *if, in Box No. VI, there are more than five earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;*
2. *If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.*

**Continuation of Box No. IV:**

James E. Cockfield, 19,162; Thomas V. Smurzynski, 24,798; Ralph A. Loren, 29,325; Giulio A. DeConti, Jr., 31,503; Amy E. Mandragouras, 36,207; Anthony A. Laurentano, 38,220; Kevin J. Canning, 35,470; Jane E. Remillard, 38,872; DeAnn F. Smith, 36,683; Jeanne M. DiGiorgio, 41,710; Megan E. Williams, 43,270; Jeremiah Lynch, 17,425; David J. Ridders, 43,882; \* Maria Laccotripe Zacharakis, Ph.D.; Debra J. Milasincic, 46,931; David R. Burns, 46,590; Sean D. Detweiler, 42,482; Cynthia L. Kanik, Ph.D., 37,320; Theodore R. West, 47,202; Hathaway P. Russell, 46,488; John S. Curran, 50,445; Lisa M. DiRocco, 51,619; Danielle L. Herritt, 43,670; Cynthia M. Soroos, 53,623; Jonathan M. Sparks, Ph.D., 53,624; Merideth C. Arnold, 52,568; Peter W. Dini, Ph.D., 52,821; Andrina Williams Zink, 54,539; and John D. Lanza, 40,060  
 \* Limited Recognition Under 37 C.F.R. § 10.9(b)

Sheet No. 6 of 7

**Box No. VI PRIORITY CLAIM**

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application:* regional Office	international application receiving Office
item (1)				
item (2)				
item (3)				
item (4)				
item (5)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☐ all items   
 ☐ item (1)   
 ☐ item (2)   
 ☐ item (3)   
 ☐ item (4)   
 ☐ item (5)   
 ☐ other, see Supplemental Box

\* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)):

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA/EP

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

**Box No. VIII DECLARATIONS**

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

Number of  
declarations

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> Box No. VIII (i)   | Declaration as to the identity of the inventor   | : |
| <input type="checkbox"/> Box No. VIII (ii)  | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent             | : |
| <input type="checkbox"/> Box No. VIII (iii) | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application | : |
| <input type="checkbox"/> Box No. VIII (iv)  | Declaration of inventorship (only for the purposes of the designation of the United States of America)                               | : |
| <input type="checkbox"/> Box No. VIII (v)   | Declaration as to non-prejudicial disclosures or exceptions to lack of novelty   | : |

## Box No. IX CHECK LIST; LANGUAGE OF FILING


This international application contains:	This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):	Number of items
(a) In paper form, the following number of sheets:	1. <input checked="" type="checkbox"/> fee calculation sheet	<input checked="" type="checkbox"/>
request (including declaration sheets) : 7	2. <input type="checkbox"/> original separate signed power of attorney	:
description (excluding sequence listings and/or tables related thereto) : 57	3. <input type="checkbox"/> original general power of attorney	:
claims : 3	4. <input type="checkbox"/> copy of general power of attorney; reference number, if any: :	:
abstract : 1	5. <input type="checkbox"/> statement explaining lack of signature :	:
drawings : 5	6. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): :	:
Sub-total number of sheets : 74	7. <input type="checkbox"/> translation of international application into (language): :	:
sequence listings : 16	8. <input type="checkbox"/> separate indications concerning deposited microorganisms or other biological material :	:
tables related thereto :	9. <input checked="" type="checkbox"/> sequence listing in computer readable form (Indicate type and number of carriers)	:
(for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below)	(i.) <input checked="" type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application) : [diskette] (2)	:
Total number of sheets : 89	(ii) <input type="checkbox"/> (only where check-box (b)(i) or (c)(i) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter :	:
(b) <input type="checkbox"/> only in computer readable form (Section 801(a)(i))	(iii) <input checked="" type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listings part mentioned in left column : [X]	:
(i) <input type="checkbox"/> sequence listings	10. <input type="checkbox"/> tables in computer readable form related to sequence listings (Indicate type and number of carriers)	:
(ii) <input type="checkbox"/> tables related thereto	(i) <input type="checkbox"/> copy submitted for the purposes of international search under Section 802 (b-quarter) only (and not as part of the international application) :	:
(c) <input type="checkbox"/> also in computer readable form (Section 801(a)(ii))	(ii) <input type="checkbox"/> (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including where applicable, the copy for the purposes of international search under Section 802 (b-quarter) :	:
(i) <input type="checkbox"/> sequence listings	(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column :	:
(ii) <input type="checkbox"/> tables related thereto	11. <input checked="" type="checkbox"/> other (specify): Fee Calc. (1 pg); Trans. Ltr. to the USRO (1 pg); Application consisting of 57 pgs of spec., 3 pgs. Of claims, 1 pg abstract and 5 sheets of drawings; Paper copy of the Seq. Listing (16 pgs); Trans. Ltr. Re: Seq. Listing (1 pg); Diskette cont. Seq. List. (1 diskette); Cert. of Express Mailing (1 page); and Return Receipt Postcard.	:
Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the		
<input type="checkbox"/> sequence listings:		
<input type="checkbox"/> tables related thereto:		
(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)		

Figure of the drawings which should accompany the abstract:

Language of filing of the international application: English

## Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

  
 Lisa M. DiRocco, Agent for BASF Aktiengesellschaft, et  
 18 December 2003

For receiving Office use only	
1. Date of actual receipt of the purported international application: <b>0120 Rec'd PCT/IB 18 DEC 2003</b>	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): <b>ISA / EP</b>	6. <input checked="" type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

## METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

### Background of the Invention

5           The industrial production of the amino acid lysine has become an economically important industrial process. lysine is used commercially as an animal feed supplement, because of its ability to improve the quality of feed by increasing the absorption of other amino acids, in human medicine, particularly as ingredients of infusion solutions, and in the pharmaceutical industry.

10           Commercial production of this lysine is principally done utilizing the gram positive *Corynebacterium glutamicum*, *Brevibacterium flavum* and *Brevibacterium lactofermentum* (Kleemann, A., et. al., "Amino Acids," in ULLMANN'S  
ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY, vol. A2, pp.57-97, Weinham:  
VCH-Verlagsgesellschaft (1985)). These organisms presently account for the  
15           approximately 250,000 tons of lysine produced annually. A significant amount of research has gone into isolating mutant bacterial strains which produce larger amounts of lysine. Microorganisms employed in microbial process for amino acid production are divided into 4 classes: wild-type strain, auxotrophic mutant, regulatory mutant and  
20           auxotrophic regulatory mutant (K. Nakayama *et al.*, in *Nutritional Improvement of Food and Feed Proteins*, M. Friedman, ed., (1978), pp. 649-661). Mutants of *Corynebacterium* and related organisms enable inexpensive production of amino acids from cheap carbon sources, *e.g.*, molasses, acetic acid and ethanol, by direct fermentation. In addition, the stereospecificity of the amino acids produced by  
25           fermentation (the L isomer) makes the process advantageous compared with synthetic processes.

          Another method in improving the efficiency of the commercial production of lysine is by investigating the correlation between lysine production and metabolic flux through the pentose phosphate pathway. Given the economic importance of lysine production by the fermentive process, the biochemical pathway for lysine  
30           synthesis has been intensively investigated, ostensibly for the purpose of increasing the total amount of lysine produced and decreasing production costs (reviewed by Sahm *et al.*, (1996) *Ann. N. Y. Acad. Sci.* 782:25-39). There has been some success in using metabolic engineering to direct the flux of glucose derived carbons toward aromatic amino acid formation (Flores, N. *et al.*, (1996) *Nature Biotechnol.* 14:620-623). Upon  
35           cellular absorption, glucose is phosphorylated with consumption of  
phosphoenolpyruvate (phosphotransferase system) (Malin & Bourd, (1991) *Journal of Applied Bacteriology* 71, 517-523) and is then available to the cell as glucose-6-phosphate. Sucrose is converted into fructose and glucose-6-phosphate by a

phosphotransferase system (Shio *et al.*, (1990) *Agricultural and Biological Chemistry* 54, 1513-1519) and invertase reaction (Yamamoto *et al.*, (1986) *Journal of Fermentation Technology* 64, 285-291).

During glucose catabolism, the enzymes glucose-6-phosphate dehydrogenase (EC 1.1.14.9) and glucose-6-phosphate isomerase (EC 5.3.1.9) compete for the substrate glucose-6-phosphate. The enzyme glucose-6-phosphate isomerase catalyses the first reaction step of the Embden-Meyerhof-Parnas pathway, or glycolysis, namely conversion into fructose-6-phosphate. The enzyme glucose-6-phosphate dehydrogenase catalyses the first reaction step of the oxidative portion of the pentose phosphate cycle, namely conversion into 6-phosphogluconolactone.

In the oxidative portion of the pentose phosphate cycle, glucose-6-phosphate is converted into ribulose-5-phosphate, so producing reduction equivalents in the form of NADPH. As the pentose phosphate cycle proceeds further, pentose phosphates, hexose phosphates and triose phosphates are interconverted. Pentose phosphates, such as for example 5-phosphoribosyl-1-pyrophosphate are required, for example, in nucleotide biosynthesis. 5-Phosphoribosyl-1-pyrophosphate is moreover a precursor for aromatic amino acids and the amino acid L-histidine. NADPH acts as a reduction equivalent in numerous anabolic biosyntheses. Four molecules of NADPH are thus consumed for the biosynthesis of one molecule of lysine from oxalacetic acid. Thus, carbon flux towards oxaloacetate (OAA) remains constant regardless of system perturbations (J. Vallino *et al.*, (1993) *Biotechnol. Bioeng.*, 41, 633-646).

### Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes, *e.g.*, lactate dehydrogenase, of the pentose phosphate pathway in *Corynebacterium glutamicum*, and the discovery that deregulation, *e.g.*, decreasing expression or activity of lactate dehydrogenase results in increased lysine production. Furthermore, it has been found that increasing the carbon yield during production of lysine by deregulating, *e.g.*, decreasing, lactate dehydrogenase expression or activity leads to increased lysine production. In one embodiment, the carbon source is fructose or sucrose. Accordingly, the present invention provides methods for increasing production of lysine by microorganisms, *e.g.*, *C. glutamicum*, where fructose or sucrose is the substrate.

Accordingly, in one aspect, the invention provides methods for increasing metabolic flux through the pentose phosphate pathway in a microorganism comprising culturing a microorganism comprising a gene which is deregulated under conditions such that metabolic flux through the pentose phosphate pathway is increased. In one embodiment, the microorganism is fermented to produce a fine chemical, *e.g.*, lysine. In

another embodiment, fructose or sucrose is used as a carbon source. In still another embodiment, the gene is lactate dehydrogenase. In a related embodiment, the lactate dehydrogenase gene is derived from *Corynebacterium*, e.g., *Corynebacterium glutamicum*. In another embodiment, lactate dehydrogenase gene is underexpressed. In a further embodiment, the protein encoded by the lactate dehydrogenase gene has decreased activity. In another embodiment, the microorganism further comprises one or more additional deregulated genes.

In one embodiment, the microorganisms used in the methods of the invention belong to the genus *Corynebacterium*, e.g., *Corynebacterium glutamicum*.

In another aspect, the invention provides methods for producing a fine chemical comprising fermenting a microorganism in which lactate dehydrogenase is deregulated and accumulating the fine chemical, e.g., lysine, in the medium or in the cells of the microorganisms, thereby producing a fine chemical. In one embodiment, the methods include recovering the fine chemical. In another embodiment, the lactate dehydrogenase gene is underexpressed. In yet another embodiment, fructose or sucrose is used as a carbon source.

In one aspect, lactate dehydrogenase is derived from *Corynebacterium glutamicum* and comprises the nucleotide sequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:2.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

### **Brief Description of the Drawings**

**Figure 1:** is a schematic representation of the pentose biosynthetic pathway.

**Figure 2:** Comparison of relative mass isotopomer fractions of secreted lysine and trehalose measured by GC/MS in tracer experiments of *Corynebacterium glutamicum* ATCC 21526 during lysine production on glucose and fructose.

**Figure 3:** *In vivo* carbon flux distribution in the central metabolism of *Corynebacterium glutamicum* ATCC 21526 during lysine production on glucose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopomer modeling for  $^{13}\text{C}$  tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively. Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux

reversibilities. All fluxes are expressed as a molar percentage of the mean specific glucose uptake rate ( $1.77 \text{ mmol g}^{-1} \text{ h}^{-1}$ ).

5 **Figure 4:** *In vivo* carbon flux distribution in the central metabolism of *Corynebacterium glutamicum* ATCC 21526 during lysine production on fructose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopomer modeling for  $^{13}\text{C}$  tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively. Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the  
10 fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux reversibilities. All fluxes are expressed as a molar percentage of the mean specific fructose uptake rate ( $1.93 \text{ mmol g}^{-1} \text{ h}^{-1}$ ).

15 **Figure 5:** Metabolic network of the central metabolism for glucose-grown (A) and fructose-grown (B) lysine producing *Corynebacterium glutamicum* including transport fluxes, anabolic fluxes and fluxes between intermediary metabolite pools.

#### Detailed Description of the Invention

20 The present invention is based at least in part, on the identification of genes, *e.g.*, *Corynebacterium glutamicum* genes, which encode essential enzymes of the pentose phosphate pathway. The present invention features methods comprising manipulating the pentose phosphate biosynthetic pathway in a microorganism, *e.g.*, *Corynebacterium glutamicum* such that the carbon yield is increased and certain  
25 desirable fine chemicals, *e.g.*, lysine, are produced, *e.g.*, produced at increased yields. In particular, the invention includes methods for producing fine chemicals, *e.g.*, lysine, by fermentation of a microorganism, *e.g.*, *Corynebacterium glutamicum*, having deregulated, *e.g.*, decreased, lactate dehydrogenase expression or activity. In one embodiment, fructose or saccharose is used as a carbon source in the fermentation of the  
30 microorganism. Fructose has been established to be a less efficient substrate for the production of fine chemicals, *e.g.*, lysine, from microorganisms. However, the present invention provides methods for optimizing production of lysine by microorganisms, *e.g.*, *C. glutamicum* where fructose or sucrose is the substrate. Deregulation, *e.g.*, reduction, of lactate dehydrogenase expression or activity leads to a higher flux through the pentose  
35 phosphate pathway, resulting in increased NADPH generation and increased lysine yield.

The term "pentose phosphate pathway" includes the pathway involving pentose phosphate enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, *e.g.*, lysine. The pentose phosphate pathway converts glucose molecules into biochemically useful smaller molecule.

In order that the present invention may be more readily understood, certain terms are first defined herein.

The term "pentose phosphosphate biosynthetic pathway" includes the biosynthetic pathway involving pentose phosphate biosynthetic genes, enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, *e.g.*, lysine. The term "pentose phosphosphate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of fine chemicals, *e.g.*, lysine, in a microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of fine chemicals, *e.g.*, lysine, *in vitro*.

The term "pentose phosphosphate biosynthetic pathway protein" or "pentose phosphosphate biosynthetic pathway enzyme" includes a those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly or indirectly involved in the pentose phosphosphate biosynthetic pathway, *e.g.*, the lactate dehydrogenase enzyme.

The term "pentose phosphosphate biosynthetic pathway gene" includes a those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes which are directly or indirectly involved in the pentose phosphosphate biosynthetic pathway, *e.g.*, the lactate dehydrogenase gene.

The term "amino acid biosynthetic pathway gene" is meant to include those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of amino acids, *e.g.*, lactate dehydrogenase. These genes may be identical to those which naturally occur within a host cell and are involved in the synthesis of any amino acid, and particularly lysine, within that host cell.

The term "lysine biosynthetic pathway gene" includes those genes and genes fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly or indirectly involved in the synthesis of lysine, *e.g.*, lactate dehydrogenase. These genes can be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such genes, for example, the genes can contain modifications or mutations which do not significantly affect the biological activity of the encoded protein. For example, the natural gene can be modified by mutagenesis or by



introducing or substituting one or more nucleotides or by removing nonessential regions of the gene. Such modifications are readily performed by standard techniques.

The term "lysine biosynthetic pathway protein" is meant to include those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly involved in the synthesis of lysine. These proteins can be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such proteins, for example, the proteins can contain modifications or mutations which do not significantly affect the biological activity of the protein. For example, the natural protein can be modified by mutagenesis or by introducing or substituting one or more amino acids, preferably by conservative amino acid substitution, or by removing nonessential regions of the protein. Such modifications are readily performed by standard techniques. Alternatively, lysine biosynthetic proteins can be heterologous to the particular host cell. Such proteins can be from any organism having genes encoding proteins having the same, or similar, biosynthetic roles.

The term, "carbon flux" refers to the number of glucose molecules which proceed down a particular metabolic path relative to competing paths. In particular, increased NADPH within a microorganism is achieved by altering the carbon flux distribution between the glycolytic and pentose phosphate pathways of that organism.

"Lactate dehydrogenase activity" includes any activity exerted by a lactate dehydrogenase protein, polypeptide or nucleic acid molecule as determined *in vivo*, or *in vitro*, according to standard techniques. Lactate dehydrogenase is present in prokaryotic and eukaryotic organisms. Preferably, a lactate dehydrogenase activity includes the catalysis of the reversible NAD-dependent interconversion of pyruvate to lactate. In vertebrate muscles and in lactic acid bacteria it represents the final step in anaerobic glycolysis.

The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described *e.g.* in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (*e.g.*, arachidonic acid), diols (*e.g.*, propane diol, and butane diol), carbohydrates (*e.g.*, hyaluronic acid and trehalose), aromatic compounds (*e.g.*, aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and

references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), and all other chemicals described in Gutcho (1983) *Chemicals by Fermentation*, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.

## 10 *Amino Acid Metabolism and Uses*

Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term "amino acid" is art-recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins. Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. *Biochemistry*, 3<sup>rd</sup> edition, pages 578-590 (1988)). The 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.

Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/L-

methionine are common feed additives. (Leuchtenberger, W. (1996) Amino acids – technical production and use, p. 466-502 in Rehm *et al.* (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of  $\alpha$ -ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transfer of the side-chain  $\beta$ -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3<sup>rd</sup> ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid

biosynthetic pathways, see Stryer, L. Biochemistry, 3<sup>rd</sup> ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

5     *Vitamin, Cofactor, and Nutraceutical Metabolism and Uses*

Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, 15 "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. 20 Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, 25 G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – 30 Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCs Press: Champaign, IL X, 374 S).

Thiamin (vitamin B<sub>1</sub>) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B<sub>2</sub>) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5'-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The 35 family of compounds collectively termed 'vitamin B<sub>6</sub>' (e.g., pyridoxine, pyridoxamine, pyridoxa-5'-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate

(pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)- $\beta$ -alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of  $\beta$ -alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to  $\beta$ -alanine and for the condensation to pantothenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5'-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B<sub>5</sub>), pantetheine (and its derivatives) and coenzyme A.

Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins. Lipic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the  $\alpha$ -ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5'-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.

Corrinoids (such as the cobalamines and particularly vitamin B<sub>12</sub>) and porphyrines belong to a group of chemicals characterized by a tetrapyrrole ring system. The biosynthesis of vitamin B<sub>12</sub> is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known.

Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.

The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B<sub>6</sub>, pantothenate, and biotin. Only Vitamin B<sub>12</sub> is produced solely by fermentation, due to the complexity of its synthesis. *In vitro* methodologies require significant inputs of materials and time, often at great cost.

*Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses*

Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).

Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of *de novo* pyrimidine and purine biosynthesis as chemotherapeutic agents." *Med. Res. Reviews* 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." *Curr. Opin. Struct. Biol.* 5: 752-757; (1995) *Biochem Soc. Transact.* 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) *Nucleotides and Related Compounds in Biotechnology* vol. 6, Rehm *et al.*, eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.

The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) "*de novo* purine nucleotide biosynthesis", in: *Progress in Nucleic Acid-Research and Molecular Biology*, vol. 42, Academic Press:, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides", Chapter 8 in: *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York). Purine metabolism has been the subject of

intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'-phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5'-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.

#### 15 *Trehalose Metabolism and Uses*

Trehalose consists of two glucose molecules, bound in  $\alpha$ ,  $\alpha$ -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto *et al.*, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) *Trends Biotech.* 16: 460-467; Paiva, C.L.A. and Panek, A.D. (1996) *Biotech. Ann. Rev.* 2: 293-314; and Shiosaka, M. (1997) *J. Japan* 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.

25

#### I. *Recombinant Microorganisms and Methods for Culturing Microorganisms Such That A Fine Chemical is Produced*

The methodologies of the present invention feature microorganisms, *e.g.*, recombinant microorganisms, preferably including vectors or genes (*e.g.*, wild-type and/or mutated genes) as described herein and/or cultured in a manner which results in the production of a desired fine chemical, *e.g.*, lysine. The term "recombinant" microorganism includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) which has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived. Preferably, a "recombinant" microorganism of the present invention has been genetically engineered such that it underexpresses at least one bacterial gene or

35

gene product as described herein, preferably a biosynthetic enzyme encoding-gene, *e.g.*, lactate dehydrogenase, included within a recombinant vector as described herein and/or a biosynthetic enzyme, *e.g.*, lactate dehydrogenase expressed from a recombinant vector. The ordinary skilled will appreciate that a microorganism expressing or underexpressing

5 a gene product produces or underproduces the gene product as a result of underexpression of nucleic acid sequences and/or genes encoding the gene product. In one embodiment, the recombinant microorganism has decreased biosynthetic enzyme, *e.g.*, lactate dehydrogenase, activity.

The term "manipulated microorganism" includes a microorganism that has been

10 engineered (*e.g.*, genetically engineered) or modified such that results in the disruption or alteration of a metabolic pathway so as to cause a change in the metabolism of carbon. An enzyme is "underexpressed" in a metabolically engineered cell when the enzyme is expressed in the metabolically engineered cell at a lower level than the level at which it is expressed in a comparable wild-type cell, including, but not limited to,

15 situations where there is no expression at all. Underexpression of the gene may lead to decreased activity of the protein encoded by the gene, *e.g.*, lactate dehydrogenase.

Modification or engineering of such microorganisms can be according to any methodology described herein including, but not limited to, deregulation of a biosynthetic pathway and/or underexpression of at least one biosynthetic enzyme. A

20 "manipulated" enzyme (*e.g.*, a "manipulated" biosynthetic enzyme) includes an enzyme, the expression or production of which has been altered or modified such that at least one upstream or downstream precursor, substrate or product of the enzyme is altered or modified, *e.g.*, has decreased activity, for example, as compared to a corresponding wild-type or naturally occurring enzyme.

25 The term "underexpressed" or "underexpression" includes expression of a gene product (*e.g.*, a pentose phosphate biosynthetic enzyme) at a lower than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically manipulated (*e.g.*, genetically engineered) to express a level of gene product

30 at a lesser level than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. Genetic manipulation can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by removing strong promoters, inducible promoters or multiple promoters), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a

35 ribosome binding site or transcription terminator, decreasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene



and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, or other methods to knock-out or block expression of the target protein).

5 In another embodiment, the microorganism can be physically or environmentally manipulated to underexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to decrease transcription of a  
10 particular gene and/or translation of a particular gene product such that transcription and/or translation are decreased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are decreased.

The term "deregulated" or "deregulation" includes the alteration or  
15 modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is decreased, thereby decreasing the activity of the gene product. The phrase "deregulated  
20 pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism arises from the particular phenomenon  
25 of microorganisms in which more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon".

The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more,  
30 preferably at least two, structural genes (*e.g.*, genes encoding enzymes, for example, biosynthetic enzymes). Expression of the structural genes can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The structural genes can be transcribed to give a single mRNA that encodes all of the structural proteins. Due to the coordinated regulation of  
35 genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of each gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding

strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, decreasing the copy  
 5 number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor  
 10 proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

A particularly preferred "recombinant" microorganism of the present invention has been genetically engineered to underexpress a bacterially-derived gene or  
 15 gene product. The term "bacterially-derived" or "derived-from", for example bacteria, includes a gene which is naturally found in bacteria or a gene product which is encoded by a bacterial gene (e.g., encoded by lactate dehydrogenase).

The methodologies of the present invention feature recombinant microorganisms which underexpress one or more genes, e.g., the lactate dehydrogenase  
 20 gene or have decreased the lactate dehydrogenase activity. A particularly preferred recombinant microorganism of the present invention (e.g., *Corynebacterium glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum*, and *Corynebacterium thermoaminogenes*, etc.) has been genetically engineered to underexpress a biosynthetic enzyme (e.g., lactate dehydrogenase, the amino acid  
 25 sequence of SEQ ID NO:2 or encoded by the nucleic acid sequence of SEQ ID NO:1).

Other preferred "recombinant" microorganisms of the present invention have an enzyme deregulated in the pentose phosphate pathway. The phrase  
 "microorganism having a deregulated pentose phosphate pathway" includes a microorganism having an alteration or modification in at least one gene encoding an  
 30 enzyme of the pentose phosphate pathway or having an alteration or modification in an operon including more than one gene encoding an enzyme of the pentose phosphate pathway. A preferred "microorganism having a deregulated pentose phosphate pathway" has been genetically engineered to underexpress a *Corynebacterium* (e.g., *C. glutamicum*) biosynthetic enzyme (e.g., has been engineered to underexpress lactate  
 35 dehydrogenase).

In another preferred embodiment, a recombinant microorganism is designed or engineered such that one or more pentose phosphate biosynthetic enzyme is underexpressed or deregulated.

In another preferred embodiment, a microorganism of the present invention underexpresses or is mutated for a gene or biosynthetic enzyme (*e.g.*, a pentose phosphate biosynthetic enzyme) which is bacterially-derived. The term "bacterially-derived" or "derived-from", for example bacteria, includes a gene product  
 5 (*e.g.*, lactate dehydrogenase) which is encoded by a bacterial gene.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive microorganism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a  
 10 microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Corynebacterium*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Corynebacterium glutamicum*, *Corynebacterium*  
 15 *acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the recombinant microorganism is *Corynebacterium glutamicum*.

An important aspect of the present invention involves culturing the recombinant microorganisms described herein, such that a desired compound (*e.g.*, a  
 20 desired fine chemical) is produced. The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a  
 25 microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism. Carbon sources which may be used include sugars and carbohydrates, such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as for example soy oil, sunflower oil, peanut oil and  
 30 coconut oil, fatty acids, such as for example palmitic acid, stearic acid and linoleic acid, alcohols, such as for example glycerol and ethanol, and organic acids, such as for example acetic acid. In a preferred embodiment, fructose or sucrose are used as carbon sources. These substances may be used individually or as a mixture.

Nitrogen sources which may be used comprise organic compounds  
 35 containing nitrogen, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources may be used individually or as a mixture. Phosphorus

sources which may be used are phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding salts containing sodium. The culture medium must furthermore contain metal salts, such as for example magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such as amino acids and vitamins may also be used in addition to the above-stated substances. Suitable precursors may furthermore be added to the culture medium. The stated feed substances may be added to the culture as a single batch or be fed appropriately during cultivation.

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art. For example, basic compounds such as sodium hydroxide, potassium hydroxide, ammonia, or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used to appropriately control the pH of the culture.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (*e.g.*, oxygen) to result in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the growth vessel (*e.g.*, fermentor) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (*e.g.*, through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents such as fatty acid polyglycol esters).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 45°C or between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired fine chemical, *e.g.*, lysine. A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired fine chemical, *e.g.*, lysine is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired fine chemical or to obtain desired yields of the particular fine chemical, *e.g.*, lysine, being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a fine chemical (*e.g.*, lysine). Preferably, culturing is continued for a time sufficient to substantially reach maximal production of the fine chemical. In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In another embodiment, culturing is continued for a time sufficient to reach production yields of a fine chemical, for example, cells are cultured such that at least about 15 to 20 g/L of a fine chemical are produced, at least about 20 to 25 g/L of a fine chemical are produced, at least about 25 to 30 g/L of a fine chemical are produced, at least about 30 to 35 g/L of a fine chemical are produced, at least about 35 to 40 g/L of a fine chemical are produced, at least about 40 to 50 g/L of a fine chemical are produced, at least about 50 to 60 g/L of a fine chemical are produced, at least about 60 to

70 g/L of a fine chemical are produced, at least about 70 to 80 g/L of a fine chemical are produced, at least about 80 to 90 g/L of a fine chemical are produced, at least about 90 to 100 g/L of a fine chemical are produced, at least about 100 to 110 g/L of a fine chemical are produced, at least about 110 to 120 g/L of a fine chemical are produced, at least about 120 to 130 g/L of a fine chemical are produced, at least about 130 to 140 g/L of a fine chemical are produced, or at least about 140 to 160 g/L of a fine chemical are produced. In yet another embodiment, microorganisms are cultured under conditions such that a preferred yield of a fine chemical, for example, a yield within a range set forth above, is produced in about 24 hours, in about 36 hours, in about 40 hours, in about 48 hours, in about 72 hours, in about 96 hours, in about 108 hours, in about 122 hours, or in about 144 hours.

The methodology of the present invention can further include a step of recovering a desired fine chemical, *e.g.*, lysine. The term "recovering" a desired fine chemical, *e.g.*, lysine includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a fine chemical, *e.g.*, lysine, can be recovered from culture media by first removing the microorganisms from the culture. Media is then passed through or over a cation exchange resin to remove unwanted cations and then through or over an anion exchange resin to remove unwanted inorganic anions and organic acids having stronger acidities than the fine chemical of interest (*e.g.*, lysine).

Preferably, a desired fine chemical of the present invention is "extracted", "isolated" or "purified" such that the resulting preparation is substantially free of other components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other components" includes preparations of desired compound in which the compound is separated (*e.g.*, purified or partially purified) from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of

other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation byproducts).

In an alternative embodiment, the desired fine chemical, *e.g.*, lysine, is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) supernatant is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

## II. Methods of Producing A Fine Chemical Independent of Precursor

### Feed Requirements

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one pentose phosphate pathway biosynthetic precursor such that fine chemicals, *e.g.*, lysine, are produced. The term "pentose phosphate pathway biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase pentose phosphate biosynthesis. In one embodiment, the pentose phosphate biosynthetic precursor or precursor is glucose. In another embodiment, the pentose phosphate biosynthetic precursor is fructose. The amount of glucose or fructose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of a fine chemical *e.g.*, lysine). Pentose phosphate biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder). Moreover, pentose phosphate biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

Providing pentose phosphate biosynthetic precursors in the pentose phosphate biosynthetic methodologies of the present invention, can be associated with high costs, for example, when the methodologies are used to produce high yields of a fine chemical. Accordingly, preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes (*e.g.*, at least one pentose phosphate biosynthetic enzyme) manipulated such

that lysine or other desired fine chemicals are produced in a manner independent of precursor feed. The phrase "a manner independent of precursor feed", for example, when referring to a method for producing a desired compound includes an approach to or a mode of producing the desired compound that does not depend or rely on precursors being provided (*e.g.*, fed) to the microorganism being utilized to produce the desired compound. For example, microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requiring no feeding of the precursors glucose or fructose.

Alternative preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes manipulated such that lysine or other fine chemicals are produced in a manner substantially independent of precursor feed. The phrase "a manner substantially independent of precursor feed" includes an approach to or a method of producing the desired compound that depends or relies to a lesser extent on precursors being provided (*e.g.*, fed) to the microorganism being utilized. For example, microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requiring feeding of substantially reduced amounts of the precursors glucose or fructose.

Preferred methods of producing desired fine chemicals in a manner independent of precursor feed or alternatively, in a manner substantially independent of precursor feed, involve culturing microorganisms which have been manipulated (*e.g.*, designed or engineered, for example, genetically engineered) such that expression of at least one pentose phosphate biosynthetic enzyme is modified. For example, in one embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that the production of at least one pentose phosphate biosynthetic enzyme is deregulated. In a preferred embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that it has a deregulated biosynthetic pathway, for example, a deregulated pentose phosphate biosynthesis pathway, as defined herein. In another preferred embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that at least one pentose phosphate biosynthetic enzyme, *e.g.*, lactate dehydrogenase is underexpressed.

### III. High Yield Production Methodologies

A particularly preferred embodiment of the present invention is a high yield production method for producing a fine chemical, *e.g.*, lysine, comprising culturing a manipulated microorganism under conditions such that lysine is produced at a significantly high yield. The phrase "high yield production method", for example, a high yield production method for producing a desired fine chemical, *e.g.*, lysine, includes a method that results in production of the desired fine chemical at a level which



is elevated or above what is usual for comparable production methods. Preferably, a high yield production method results in production of the desired compound at a significantly high yield. The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 2 g/L, 10 g/L, 15 g/L, 20 g/L, 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, or 200 g/L.

The invention further features a high yield production method for producing a desired fine chemical, *e.g.*, lysine, that involves culturing a manipulated microorganism under conditions such that a sufficiently elevated level of compound is produced within a commercially desirable period of time. In an exemplary embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 15-20 g/L in 5 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 25-40 g/L in 10 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 50-100 g/L in 20 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 140-160 g/L in 40 hours, for example, greater than 150 g/L in 40 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 130-160 g/L in 40 hours, for example, greater than 135, 145 or 150 g/L in 40 hours. Values and ranges included and/or intermediate within the ranges set forth herein are also intended to be within the scope of the present invention. For example, lysine production at levels of at least 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, and 150 g/L in 40 hours are intended to be included within the range of 140-150 g/L in 40 hours. In another example, ranges of 140-145 g/L or 145-150 g/L are intended to be included within the range of 140-150 g/L in 40 hours. Moreover, the skilled artisan will appreciate that culturing a manipulated microorganism to achieve a

production level of, for example, "140-150 g/L in 40 hours" includes culturing the microorganism for additional time periods (e.g., time periods longer than 40 hours), optionally resulting in even higher yields of lysine being produced.

5

#### IV. Isolated Nucleic Acid Molecules and Genes

Another aspect of the present invention features isolated nucleic acid molecules that encode proteins (e.g., *C. glutamicum* proteins), for example, *Corynebacterium* pentose phosphate biosynthetic enzymes (e.g., *C. glutamicum* pentose phosphate enzymes) for use in the methods of the invention. In one embodiment, the isolated nucleic acid molecules used in the methods of the invention are lactate dehydrogenase nucleic acid molecules.

The term "nucleic acid molecule" includes DNA molecules (e.g., linear, circular, cDNA or chromosomal DNA) and RNA molecules (e.g., tRNA, rRNA, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The term "isolated" nucleic acid molecule includes a nucleic acid molecule which is free of sequences which naturally flank the nucleic acid molecule (i.e., sequences located at the 5' and 3' ends of the nucleic acid molecule) in the chromosomal DNA of the organism from which the nucleic acid is derived. In various embodiments, an isolated nucleic acid molecule can contain less than about 10 kb, 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the nucleic acid molecule in chromosomal DNA of the microorganism from which the nucleic acid molecule is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular materials when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

The term "gene," as used herein, includes a nucleic acid molecule (e.g., a DNA molecule or segment thereof), for example, a protein or RNA-encoding nucleic acid molecule, that in an organism, is separated from another gene or other genes, by intergenic DNA (i.e., intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). A gene may direct synthesis of an enzyme or other protein molecule (e.g., may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. Individual genes contained within an operon may overlap without intergenic DNA between said individual genes. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the

gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or distinct protein or RNA molecule, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Corynebacterium* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Corynebacterium* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Corynebacterium* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

In one aspect, the methods of the present invention features use of isolated lactate dehydrogenase nucleic acid sequences or genes.

In a preferred embodiment, the nucleic acid or gene is derived from *Corynebacterium* (*e.g.*, is *Corynebacterium*-derived). The term "derived from *Corynebacterium*" or "*Corynebacterium*-derived" includes a nucleic acid or gene which is naturally found in microorganisms of the genus *Corynebacterium*. Preferably, the nucleic acid or gene is derived from a microorganism selected from the group consisting of *Corynebacterium glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the nucleic acid or gene is derived from *Corynebacterium glutamicum* (*e.g.*, is *Corynebacterium glutamicum*-derived). In yet another preferred embodiment, the nucleic acid or gene is a *Corynebacterium* gene homologue (*e.g.*, is derived from a species distinct from *Corynebacterium* but having significant homology to a *Corynebacterium* gene of the present invention, for example, a *Corynebacterium* lactate dehydrogenase gene).

Included within the scope of the present invention are bacterial-derived nucleic acid molecules or genes and/or *Corynebacterium*-derived nucleic acid molecules or genes (*e.g.*, *Corynebacterium*-derived nucleic acid molecules or genes), for example, the genes identified by the present inventors, for example, *Corynebacterium* or *C. glutamicum* lactate dehydrogenase genes. Further included within the scope of the present invention are bacterial-derived nucleic acid molecules or genes and/or *Corynebacterium*-derived nucleic acid molecules or genes (*e.g.*, *C. glutamicum*-derived nucleic acid molecules or genes) (*e.g.*, *C. glutamicum* nucleic acid molecules or genes) which differ from naturally-occurring bacterial and/or *Corynebacterium* nucleic acid molecules or genes (*e.g.*, *C. glutamicum* nucleic acid

molecules or genes), for example, nucleic acid molecules or genes which have nucleic acids that are substituted, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention. In one embodiment, an isolated nucleic acid molecule comprises the nucleotide sequences set forth as SEQ ID NO:1, or encodes the amino acid sequence set forth in SEQ ID NO:2.

5 In another embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 60-65%, preferably at least about 70-75%, more preferable at least about 80-85%, and even more preferably at least about 90-95% or more identical to a nucleotide sequence set forth as SEQ ID  
10 NO:1. In another embodiment, an isolated nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent (*e.g.* high stringency)  
15 hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid  
20 molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature.

A nucleic acid molecule of the present invention (*e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1) can be isolated using standard molecular biology techniques and the sequence information provided herein. For  
25 example, nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) or can be isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based  
30 upon the sequence of SEQ ID NO:1. A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ  
35 ID NO:1.

In another embodiment, an isolated nucleic acid molecule is or includes a lactate dehydrogenase gene, or portion or fragment thereof. In one embodiment, an isolated lactate dehydrogenase nucleic acid molecule or gene comprises the nucleotide

sequence as set forth in SEQ ID NO:1 (e.g., comprises the *C. glutamicum* lactate dehydrogenase nucleotide sequence). In another embodiment, an isolated lactate dehydrogenase nucleic acid molecule or gene comprises a nucleotide sequence that encodes the amino acid sequence as set forth in SEQ ID NO:2 (e.g., encodes the *C.*

5 *glutamicum* lactate dehydrogenase amino acid sequence). In yet another embodiment, an isolated lactate dehydrogenase nucleic acid molecule or gene encodes a homologue of the lactate dehydrogenase protein having the amino acid sequence of SEQ ID NO:2. As used herein, the term "homologue" includes a protein or polypeptide sharing at least about 30-35%, preferably at least about 35-40%, more preferably at least about 40-50%,

10 and even more preferably at least about 60%, 70%, 80%, 90% or more identity with the amino acid sequence of a wild-type protein or polypeptide described herein and having a substantially equivalent functional or biological activity as said wild-type protein or polypeptide. For example, a lactate dehydrogenase homologue shares at least about 30-35%, preferably at least about 35-40%, more preferably at least about 40-50%, and even

15 more preferably at least about 60%, 70%, 80%, 90% or more identity with the protein having the amino acid sequence set forth as SEQ ID NO:2 and has a substantially equivalent functional or biological activity (i.e., is a functional equivalent) of the protein having the amino acid sequence set forth as SEQ ID NO:2 (e.g., has a substantially equivalent pantothenate kinase activity). In a preferred embodiment, an isolated lactate

20 dehydrogenase nucleic acid molecule or gene comprises a nucleotide sequence that encodes a polypeptide as set forth in SEQ ID NO:2. In another embodiment, an isolated lactate dehydrogenase nucleic acid molecule hybridizes to all or a portion of a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or hybridizes to all or a portion of a nucleic acid molecule having a nucleotide sequence that encodes a

25 polypeptide having the amino acid sequence of SEQ ID NOs:2. Such hybridization conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions can be found in *Molecular Cloning: A Laboratory Manual*, Sambrook *et al.*, Cold Spring Harbor Press, Cold Spring Harbor,

30 NY (1989), chapters 7, 9 and 11. A preferred, non-limiting example of stringent hybridization conditions includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A preferred, non-limiting example of highly stringent hybridization conditions includes hybridization in

35 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A preferred, non-limiting example of reduced stringency hybridization conditions includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X SSC

plus 50% formamide at about 40-45°C) followed by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, e.g., at 65-70°C or at 42-50°C are also intended to be encompassed by the present invention. SSPE (1X SSPE is 0.15 M NaCl, 10mM NaH<sub>2</sub>PO<sub>4</sub>, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1X SSC is 0.15 M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature ( $T_m$ ) of the hybrid, where  $T_m$  is determined according to the following equations. For hybrids less than 18 base pairs in length,  $T_m(^{\circ}\text{C}) = 2(\# \text{ of A} + \text{T bases}) + 4(\# \text{ of G} + \text{C bases})$ . For hybrids between 18 and 49 base pairs in length,  $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G} + \text{C}) - (600/\text{N})$ , where N is the number of bases in the hybrid, and  $[\text{Na}^+]$  is the concentration of sodium ions in the hybridization buffer ( $[\text{Na}^+]$  for 1X SSC = 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, PVP and the like. When using nylon membranes, in particular, an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH<sub>2</sub>PO<sub>4</sub>, 7% SDS at about 65°C, followed by one or more washes at 0.02M NaH<sub>2</sub>PO<sub>4</sub>, 1% SDS at 65°C, see e.g., Church and Gilbert (1984) *Proc. Natl. Acad. Sci. USA* 81:1991-1995, (or, alternatively, 0.2X SSC, 1% SDS). In another preferred embodiment, an isolated nucleic acid molecule comprises a nucleotide sequence that is complementary to a lactate dehydrogenase nucleotide sequence as set forth herein (e.g., is the full complement of the nucleotide sequence set forth as SEQ ID NO:1).

A nucleic acid molecule of the present invention (e.g., a lactate dehydrogenase nucleic acid molecule or gene), can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) or can be isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based upon the lactate dehydrogenase nucleotide sequences set forth herein, or flanking sequences thereof. A nucleic acid of the invention (e.g., a lactate dehydrogenase nucleic acid molecule or gene), can be amplified using cDNA, mRNA or alternatively, chromosomal DNA, as a

template and appropriate oligonucleotide primers according to standard PCR amplification techniques.

Yet another embodiment of the present invention features mutant lactate dehydrogenase nucleic acid molecules or genes. The phrase "mutant nucleic acid molecule" or "mutant gene" as used herein, includes a nucleic acid molecule or gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein that may be encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Preferably, a mutant nucleic acid molecule or mutant gene (*e.g.*, a mutant lactate dehydrogenase gene) encodes a polypeptide or protein having an increased activity (*e.g.*, having an increased lactate dehydrogenase activity) as compared to the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can have a decreased level of production of the wild-type polypeptide.

As used herein, a "decreased activity" or "decreased enzymatic activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "decreased activity" or "decreased enzymatic activity" also includes an activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene). Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein isolated or purified from a cell. Alternatively, an activity can be measured or assayed within a cell or in an extracellular medium.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant nucleic acid or mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue, as described above, in that a mutant nucleic acid or mutant gene encodes a protein or polypeptide having an altered activity, optionally

observable as a different or distinct phenotype in a microorganism expressing said mutant gene or nucleic acid or producing said mutant protein or polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid or producing said mutant protein or polypeptide. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

#### V. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (*e.g.*, recombinant DNA molecules) that include nucleic acid molecules and/or genes described herein (*e.g.*, isolated nucleic acid molecules and/or genes), preferably *Corynebacterium* genes, more preferably *Corynebacterium glutamicum* genes, even more preferably *Corynebacterium glutamicum* lactate dehydrogenase genes.

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, isolated or recombinant nucleic acid molecules and/or genes) described herein. In particular, recombinant vectors are featured that include nucleic acid sequences that encode bacterial gene products as described herein, preferably *Corynebacterium* gene products, more preferably *Corynebacterium glutamicum* gene products (*e.g.*, pentose phosphate enzymes, for example, lactate dehydrogenase).

The term "recombinant nucleic acid molecule" includes a nucleic acid molecule (*e.g.*, a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (*e.g.*, by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (*e.g.*, a recombinant DNA molecule) includes an isolated nucleic acid molecule or gene of the present invention (*e.g.*, an isolated lactate dehydrogenase gene) operably linked to regulatory sequences.



The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a lactate dehydrogenase gene or recombinant nucleic acid molecule including such lactate dehydrogenase gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs).

The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the nucleic acid molecule or gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (*e.g.*, enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the nucleotide sequence, preferably expression of a gene product encoded by the nucleotide sequence (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

The term "regulatory sequence" includes nucleic acid sequences which affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences. In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule or recombinant vector in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences, for example, to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational

regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (e.g., constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (e.g., inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (e.g., attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the regulation of transcription such that increased or constitutive transcription occurs can be removed such that expression of a gene of interest is decreased.

In one embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a pentose phosphate biosynthetic enzyme, for example lactate dehydrogenase) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Corynebacterium* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Corynebacterium*). In one embodiment, a promoter is a *Corynebacterium* promoter, preferably a strong *Corynebacterium* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Corynebacterium* or a promoter associated with a glycolytic pathway gene in *Corynebacterium*). In another embodiment, a promoter is a bacteriophage promoter.

In another embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences). The term "terminator sequences" includes regulatory sequences which serve to terminate transcription of a gene. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (e.g., by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes sequences which allow for detection of the vector containing said sequences (i.e., detectable and/or selectable markers), for example, sequences that overcome auxotrophic mutations, for example, *ura3* or *ilvE*, fluorescent markers, and/or colorimetric markers (e.g., *lacZ*/ $\beta$ -galactosidase), and/or antibiotic resistance genes (e.g., *amp* or *tet*).

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance genes. The term "antibiotic resistance genes" includes sequences which promote or confer resistance to antibiotics on the host organism (e.g., *Bacillus*). In one embodiment, the antibiotic resistance genes are selected from the group consisting of *cat* (chloramphenicol resistance) genes, *tet* (tetracycline resistance) genes, *erm* (erythromycin resistance) genes, *neo* (neomycin resistance) genes and *spec* (spectinomycin resistance) genes. Recombinant vectors of the present invention can further include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *amyE* sequences can be used as homology targets for recombination into the host chromosome.

It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

#### VI. Isolated Proteins

Another aspect of the present invention features isolated proteins (e.g., isolated pentose phosphate biosynthetic enzymes, for example isolated lactate dehydrogenase). In one embodiment, proteins (e.g., isolated pentose phosphate enzymes, for example isolated lactate dehydrogenase) are produced by recombinant DNA techniques and can be isolated from microorganisms of the present invention by an appropriate purification scheme using standard protein purification techniques. In another embodiment, proteins are synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein (e.g., an isolated or purified biosynthetic enzyme) is substantially free of cellular material or other contaminating proteins from the microorganism from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, an isolated or purified protein has less than about 30% (by dry weight) of contaminating protein or chemicals, more preferably less than about 20% of contaminating protein or chemicals, still more preferably less than about 10% of contaminating protein or chemicals, and most preferably less than about 5% contaminating protein or chemicals.

In a preferred embodiment, the protein or gene product is derived from *Cornynebacterium* (e.g., is *Cornynebacterium*-derived). The term "derived from *Cornynebacterium*" or "*Cornynebacterium*-derived" includes a protein or gene product which is encoded by a *Cornynebacterium* gene. Preferably, the gene product is derived from a microorganism selected from the group consisting of *Cornynebacterium*.

*glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the protein or gene product is derived from *Corynebacterium glutamicum* (e.g., is *Corynebacterium glutamicum*-derived). The term "derived from *Corynebacterium glutamicum*" or "*Corynebacterium glutamicum*-derived" includes a protein or gene product which is encoded by a *Corynebacterium glutamicum* gene. In yet another preferred embodiment, the protein or gene product is encoded by a *Corynebacterium* gene homologue (e.g., a gene derived from a species distinct from *Corynebacterium* but having significant homology to a *Corynebacterium* gene of the present invention, for example, a *Corynebacterium* lactate dehydrogenase gene).

Included within the scope of the present invention are bacterial-derived proteins or gene products and/or *Corynebacterium*-derived proteins or gene products (e.g., *C. glutamicum*-derived gene products) that are encoded by naturally-occurring bacterial and/or *Corynebacterium* genes (e.g., *C. glutamicum* genes), for example, the genes identified by the present inventors, for example, *Corynebacterium* or *C. glutamicum* lactate dehydrogenase genes. Further included within the scope of the present invention are bacterial-derived proteins or gene products and/or *Corynebacterium*-derived proteins or gene products (e.g., *C. glutamicum*-derived gene products) that are encoded bacterial and/or *Corynebacterium* genes (e.g., *C. glutamicum* genes) which differ from naturally-occurring bacterial and/or *Corynebacterium* genes (e.g., *C. glutamicum* genes), for example, genes which have nucleic acids that are mutated, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention. For example, it is well understood that one of skill in the art can mutate (e.g., substitute) nucleic acids which, due to the degeneracy of the genetic code, encode for an identical amino acid as that encoded by the naturally-occurring gene. Moreover, it is well understood that one of skill in the art can mutate (e.g., substitute) nucleic acids which encode for conservative amino acid substitutions. It is further well understood that one of skill in the art can substitute, add or delete amino acids to a certain degree without substantially affecting the function of a gene product as compared with a naturally-occurring gene product, each instance of which is intended to be included within the scope of the present invention.

In a preferred embodiment, an isolated protein of the present invention (e.g., an isolated pentose phosphate biosynthetic enzyme, for example isolated lactate dehydrogenase) has an amino acid sequence shown in SEQ ID NO:2. In other embodiments, an isolated protein of the present invention is a homologue of the protein set forth as SEQ ID NO:2, (e.g., comprises an amino acid sequence at least about 30-40% identical, preferably about 40-50% identical, more preferably about 50-60%

identical, and even more preferably about 60-70%, 70-80%, 80-90%, 90-95% or more identical to the amino acid sequence of SEQ ID NO:2, and has an activity that is substantially similar to that of the protein encoded by the amino acid sequence of SEQ ID NO:2.

5                   To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the  
10                   corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions x 100), preferably taking into account the number of gaps and size of said gaps necessary to produce an optimal alignment.

15                   The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA*  
20                   90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST  
25                   program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Research* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and  
30                   NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (1988) *Comput Appl Biosci.* 4:11-17. Such an algorithm is incorporated into the ALIGN program available, for example, at the GENESTREAM network server, IGH Montpellier, FRANCE (<http://vega.igh.cnrs.fr>) or  
- 35 - at the ISREC server (<http://www.ch.embnet.org>). When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

In another preferred embodiment, the percent homology between two amino acid sequences can be determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4.

- 5 In yet another preferred embodiment, the percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a gap weight of 50 and a length weight of 3.

- 10 This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents, Sequence Listing, Figures, and published patent applications cited throughout this application are incorporated herein by reference.

### EXAMPLES

15

#### **General Methodology:**

- Strains.* *Corynebacterium glutamicum* ATCC 21526 was obtained from the American Type and Culture Collection (Manassas, USA). This homoserine auxotrophic strain excretes lysine during L-threonine limitation due to the bypass of concerted aspartate kinase inhibition. Precultures were grown in complex medium containing 5 g L<sup>-1</sup> of either fructose or glucose. For agar plates the complex medium was additionally amended with 12 g L<sup>-1</sup> agar. For the production of cells as inoculum for the tracer experiments and the tracer studies itself a minimal medium amended with 1 mg ml<sup>-1</sup> calcium pantothenate-HCl was used (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). In this medium concentrations of carbon source glucose or fructose, of the essential amino acids threonine, methionine and leucine and of citrate were varied as specified below.
- 20
- 25

- Cultivation.* Precultivation consisted of three steps involving (i) a starter cultivation in complex medium with cells from agar plate as inoculum, (ii) a short cultivation for adaption to minimal medium, and (iii) a prolonged cultivation on minimal medium with elevated concentrations of essential amino acids. Pre-cultures inoculated from agar plates were grown overnight in 100 ml baffled shake flasks on 10 ml complex medium. Afterwards cells were harvested by centrifugation (8800 g, 2 min, 30 °C), inoculated into minimal medium, and grown up to an optical density of 2 to obtain exponentially growing cells adapted to minimal medium. Afterwards cells were harvested by centrifugation (8800 g, 30 °C, and 2 min) including a washing step with sterile 0.9 % NaCl. They were then inoculated into 6 ml minimal medium in 50 ml
- 30
- 35

baffled shake flasks with initial concentrations of 0.30 g L<sup>-1</sup> threonine, 0.08 g L<sup>-1</sup> methionine, 0.20 g L<sup>-1</sup> leucine, and 0.57 g L<sup>-1</sup> citrate. As carbon source 70 mM glucose or 80 mM fructose were added, respectively. Cells were grown until depletion of the essential amino acids, which was checked by HPLC analysis. At the end of the growth phase cells were harvested, and washed with sterile NaCl (0.9 %). Subsequently they were transferred into 4 ml minimal tracer medium in 25 ml baffled shake flasks for metabolic flux analysis under lysine producing conditions. The tracer medium did not contain any threonine, methionine, leucine and citrate. For each carbon source two parallel flasks were incubated containing (i) 40 mM [1-<sup>13</sup>C] labeled substrate, and (ii) 20 mM [<sup>13</sup>C<sub>6</sub>] labeled substrate plus 20 mM of naturally labeled substrate, respectively. All cultivations were carried out on a rotary shaker (Inova 4230, New Brunswick, Edison, NJ, USA) at 30°C and 150 rpm.

**Chemicals.** 99% [1-<sup>13</sup>C] glucose, 99% [1-<sup>13</sup>C] fructose, 99% [<sup>13</sup>C<sub>6</sub>] glucose and 99% [<sup>13</sup>C<sub>6</sub>] fructose were purchased from Campro Scientific (Veenendaal, Netherlands). Yeast extract and tryptone were obtained from Difco Laboratories (Detroit, Michigan USA). All other applied chemicals were from Sigma (St. Louis, MI USA), Merck (Darmstadt, Germany) or Fluka (Buchs, Switzerland), respectively, and of analytical grade

**Substrate and product analysis.** Cell concentration was determined by measurement of cell density at 660 nm (OD<sub>660nm</sub>) using a photometer (Marsha Pharmacia biotech, Freiburg, Germany) or by gravimetry. The latter was determined by harvesting 10 ml of cells from cultivation broth at room temperature for 10 min at 3700 g, including a washing step with water. Washed cells were dried at 80 °C until weight constancy. The correlation factor (g biomass/OD<sub>660nm</sub>) between dry cell dry mass and OD<sub>660nm</sub> was determined as 0.353.

Concentrations of extracellular substrates and products were determined in cultivation supernatants, obtained via 3 min centrifugation at 16000 g. Fructose, glucose, sucrose, and trehalose were quantified by GC after derivatization into oxime trimethylsilyl derivatives. For this purpose a HP 6890 gas chromatograph (Hewlett Packard, Palo Alto, USA) with an HP 5MS column (5 % phenyl-methyl-siloxane-diphenyldimethylpolysiloxane, 30 m x 250 µm, Hewlett Packard, Palo Alto, CA, USA), and a quadrupole mass selective detector with electron impact ionization at 70 eV (Agilent Technologies, Waldbronn, Germany) was applied. Sample preparation included lyophilization of the culture supernatant, dissolution in pyridine, and subsequent two-step derivatization of the sugars with hydroxylamine and (trimethylsilyl)trifluoroacetamide (BSTFA) (Macherey & Nagel, Düren, Germany) (13, 14). β-D-ribose was used as internal standard for quantification. The injected sample volume was 0.2 µl. The time program for GC analysis was as follows: 150 °C (0 - 5

min), 8 °C min<sup>-1</sup> (5 – 25 min), 310 °C (25 – 35 min). Helium was used as carrier gas with a flow of 1.5 l min<sup>-1</sup>. The inlet temperature was 310 °C and the detector temperature was 320 °C. Acetate, lactate, pyruvate, 2-oxoglutarate, and dihydroxyacetone were determined by HPLC utilizing an Aminex-HPX-87H Biorad Column (300 x 7.8 mm, Hercules, CA, USA) with 4 mM sulfuric acid as mobile phase at a flow rate of 0.8 ml min<sup>-1</sup>, and UV-detection at 210 nm. Glycerol was quantified by enzymatic measurement (Boehringer, Mannheim, Germany). Amino acids were analyzed by HPLC (Agilent Technologies, Waldbronn, Germany) utilizing a Zorbax Eclipse-AAA column (150 x 4.6 mm, 5 µm, Agilent Technologies, Waldbronn Germany), with automated online derivatization (*o*-phthalaldehyde + 3-mercaptopropionic acid) at a flow rate of 2 ml min<sup>-1</sup>, and fluorescence detection. Details are given in the instruction manual.  $\alpha$ -amino butyrate was used as internal standard for quantification.

**<sup>13</sup>C labeling analysis.** The labeling patterns of lysine and trehalose in cultivation supernatants were quantified by GC-MS. Hereby single mass isotopomer fractions were determined. In the current work they are defined as M<sub>0</sub> (relative amount of non-labelled mass isotopomer fraction), M<sub>1</sub> (relative amount of single labelled mass isotopomer fraction) and corresponding terms for higher labelling. GC-MS analysis of lysine was performed after conversion into the t-butyl-dimethylsilyl (TBDMS) derivate as described previously (Rubino, F. M. 1989. J. Chromatogr. 473:125-133). Quantification of mass isotopomer distributions was performed in selective ion monitoring (SIM) mode for the ion cluster *m/z* 431-437. This ion cluster corresponds to a fragment ion, which is formed by loss of a t-butyl group from the derivatization residue, and thus includes the complete carbon skeleton of lysine (Wittmann, C., M. Hans and E. Heinzle. 2002. Analytical Biochem. 307:379-382). The labeling pattern of trehalose was determined from its trimethylsilyl (TMS) derivate as described previously (Wittmann, C., H. M. Kim and E. Heinzle. 2003. Metabolic flux analysis at miniaturized scale. submitted). The labeling pattern of trehalose was estimated via the ion cluster at *m/z* 361-367 corresponding to a fragment ion that contained an entire monomer unit of trehalose and thus a carbon skeleton equal to that of glucose 6-phosphate. All samples were measured first in scan mode therewith excluding isobaric interference between analyzed products and other sample components. All measurements by SIM were performed in duplicate. The experimental errors of single mass isotopomer fractions in the tracer experiments on fructose were 0.85% (M<sub>0</sub>), 0.16 % (M<sub>1</sub>), 0.27 % (M<sub>2</sub>), 0.35 % (M<sub>3</sub>), 0.45 % (M<sub>4</sub>) for lysine on [1-<sup>13</sup>C]-fructose, 0.87-% (M<sub>0</sub>), 0.19-% (M<sub>1</sub>), 0.44 % (M<sub>2</sub>), 0.45 % (M<sub>3</sub>), 0.88 % (M<sub>4</sub>) for trehalose on [1-<sup>13</sup>C] fructose, and 0.44 % (M<sub>0</sub>), 0.54 % (M<sub>1</sub>), 0.34 % (M<sub>2</sub>), 0.34 % (M<sub>3</sub>), 0.19 % (M<sub>4</sub>), 0.14 % (M<sub>5</sub>) and 0.52 % (M<sub>6</sub>) for trehalose on 50 % [<sup>13</sup>C<sub>6</sub>] fructose, respectively. The experimental errors of MS measurements in



glucose tracer experiments were 0.47 % ( $M_0$ ), 0.44 % ( $M_1$ ), 0.21 % ( $M_2$ ), 0.26 % ( $M_3$ ), 0.77 % ( $M_4$ ) for lysine on [1- $^{13}\text{C}$ ] glucose, 0.71 % ( $M_0$ ), 0.85 % ( $M_1$ ), 0.17 % ( $M_2$ ), 0.32 % ( $M_3$ ), 0.46 % ( $M_4$ ) for trehalose on [1- $^{13}\text{C}$ ] glucose, and 1.29 % ( $M_0$ ), 0.50 % ( $M_1$ ), 0.83 % ( $M_2$ ), 0.84 % ( $M_3$ ), 1.71 % ( $M_4$ ), 1.84 % ( $M_5$ ) and 0.58 % ( $M_6$ ) for trehalose on 50 % [ $^{13}\text{C}_6$ ] glucose, respectively.

**Metabolic modelling and parameter estimation.** All metabolic simulations were carried out on a personal computer. Metabolic network of lysine-producing *C. glutamicum* was implemented in Matlab 6.1 and Simulink 3.0 (Mathworks, Inc., Natick, MA USA). The software implementation included an isotopomer model in Simulink to calculate the  $^{13}\text{C}$  labeling distribution in the network. For parameter estimation the isotopomer model was coupled with an iterative optimization algorithm in Matlab. Details on the applied computational tools are given by Wittmann and Heinzle (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859).

The metabolic network was based on previous work and comprised glycolysis, pentose phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, anaplerotic carboxylation of pyruvate, biosynthesis of lysine and other secreted products (Tab. 1), and anabolic fluxes from intermediary precursors into biomass. In addition uptake systems for glucose and fructose were alternatively implemented. Uptake of glucose involved phosphorylation to glucose 6-phosphate via a PTS (Ohnishi, J., S. Mitsuhashi, M. Hayashi, S. Ando, H. Yokoi, K. Ochiai and M. A. Ikeda. 2002. Appl. Microbiol. Biotechnol. 58:217-223). For fructose two uptake systems were considered: (i) uptake by  $\text{PTS}_{\text{Fructose}}$  and conversion of fructose into fructose 1,6-bisphosphatase via fructose 1-phosphate and (ii) uptake by  $\text{PTS}_{\text{Mannose}}$  leading to fructose 6-phosphate, respectively (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). In addition fructose-1,6-bisphosphatase was implemented into the model to allow carbon flux in both directions in the upper glycolysis. Reactions regarded reversible were transaldolase and transketolases in the PPP. Additionally glucose 6-phosphate isomerase was considered reversible for the experiments on glucose, whereby the trehalose labeling sensitively reflected the reversibility of this enzyme. In contrast the reversibility of glucose 6-phosphate isomerase could not be determined on fructose. In fructose-grown cells, glucose 6-phosphate is exclusively formed from fructose 6-phosphate leading to identical labeling patterns for the two pools. Therefore interconversion between glucose 6-phosphate and fructose 6-phosphate by a reversible glucose 6-phosphate isomerase does not result in labeling differences that could be used for the estimation of glucose 6-phosphate isomerase reversibility. The measured labeling of lysine and trehalose was not sensitive towards (i) the reversibility of the flux between the lumped pools of phosphoenolpyruvate/pyruvate and malate/oxaloacetate and (ii) the reversibility of

malate dehydrogenase and fumarate hydratase in the TCA cycle. Accordingly these reactions were regarded irreversible. The labeling of alanine from a mixture of naturally labeled and [<sup>13</sup>C<sub>6</sub>] labeled substrate, which is sensitive for these flux parameters, was not available in this study. Based on previous results the glyoxylate pathway was assumed to be inactive (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859).

Stoichiometric data on growth, product formation, and biomass composition of *C. glutamicum* together with mass spectrometric labeling data of secreted lysine and trehalose were used to calculate metabolic flux distributions. The set of fluxes that gave minimum deviation between experimental ( $M_{i, \text{exp}}$ ) and simulated ( $M_{i, \text{calc}}$ ) mass isotopomer fractions of lysine and trehalose of the two parallel experiments was taken as best estimate for the intracellular flux distribution. As described in the appendix the two networks of glucose-grown and fructose-grown cells were over determined. A least square approach was therefore possible. As error criterion a weighted sum of least squares (SLS) was used, where  $S_{i, \text{exp}}$  is the standard deviation of the measurements (Eq. 1).

$$SLS = \sum_i \frac{(M_{i, \text{exp}} - M_{i, \text{calc}})^2}{S_{i, \text{exp}}^2} \quad (\text{Equation 1})$$

Multiple parameter initializations were applied to investigate whether an obtained flux distribution represented a global optimum. For all strains the glucose uptake flux during lysine production was set to 100 % and the other fluxes in the network are given as relative molar fluxes normalized to the glucose uptake flux.

**Statistical evaluation.** Statistical analysis of the obtained metabolic fluxes was carried out by a Monte-Carlo approach as described previously (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). For each strain, the statistical analysis was carried out by 100 parameter estimation runs, whereby the experimental data, comprising measured mass isotopomer ratios and measured fluxes, were varied statistically. From the obtained data 90 % confidence limits for the single parameters were calculated.

#### EXAMPLE I: LYSINE PRODUCTION BY *C. GLUTAMICUM* ON FRUCTOSE AND GLUCOSE

Metabolic fluxes of lysine producing *C. glutamicum* were analyzed in comparative batch cultures on glucose and fructose. For this purpose pre-grown cells were transferred into tracer medium and incubated for about 5 hours. The analysis of

substrates and products at the beginning and the end of the tracer experiment revealed drastic differences between the two carbon sources. Overall 11.1 mM lysine was produced on glucose, whereas a lower concentration of only 8.6 mM was reached on fructose. During the incubation over 5 hours, the cell concentration increased from 3.9 g L<sup>-1</sup> to 6.0 g L<sup>-1</sup> (glucose) and from 3.5 g L<sup>-1</sup> to 4.4 g L<sup>-1</sup> (fructose). Due to the fact that threonine and methionine were not present in the medium, internal sources were probably utilized by the cells for biomass synthesis. The mean specific sugar uptake rate was higher on fructose (1.93 mmol g<sup>-1</sup> h<sup>-1</sup>) compared to glucose (1.71 mmol g<sup>-1</sup> h<sup>-1</sup>). As depicted in Table 1, the obtained yields of *C. glutamicum* ATCC 21526 differed drastically between fructose and glucose. This involved the main product lysine and various byproducts. Concerning lysine, the yield on fructose was 244 mmol mol<sup>-1</sup> and thus was lower compared to the yield on glucose (281 mmol mol<sup>-1</sup>). Additionally the carbon source had a drastic influence on the biomass yield, which was reduced by almost 50% on fructose in comparison to glucose. The most significant influence of the carbon source on byproduct formation was observed for dihydroxyacetone, glycerol, and lactate. On fructose, accumulation of these byproducts was strongly enhanced. The yield for glycerol was 10 fold higher, whereas dihydroxyacetone and lactate secretion were increased by a factor of six. Dihydroxyacetone was the dominating byproduct on fructose. Due to the lower biomass yield a significantly reduced demand for anabolic precursors resulted for fructose-grown cells (Table 2).

**Table 1:** Biomass and metabolites in the stage of lysine production by *Corynebacterium glutamicum* ATCC 21526 from glucose (left) and fructose (right). Experimental yields are mean values of two parallel incubations on (i) 40 mM [<sup>13</sup>C] labeled substrate and (ii) 20 mM [<sup>13</sup>C<sub>6</sub>] labeled substrate plus 20 mM naturally labeled substrate with corresponding deviations between the two incubations. All yields are given in (mmol product) (mol)<sup>-1</sup> except the yield for biomass, which is given in (mg of dry biomass) (mmol)<sup>-1</sup>.

Yield	Lysine production on glucose	Lysine production on fructose
Biomass	54.1 ± 0.8	28.5 ± 0.0
Lysine	281.0 ± 2.0	244.4 ± 23.3
Valine	0.1 ± 0.0	0.0 ± 0.0
Alanine	0.1 ± 0.0	0.4 ± 0.1
Glycine	6.6 ± 0.0	7.1 ± 0.4
Dihydroxyacetone	26.3 ± 15.3	156.6 ± 25.8
Glycerol	3.8 ± 2.4	38.4 ± 3.9
Trehalose	3.3 ± 0.5	0.9 ± 0.1
α-Ketoglutarate	1.6 ± 0.4	6.5 ± 0.3
Acetate	45.1 ± 0.3	36.2 ± 5.7
Pyruvate	1.2 ± 0.4	2.1 ± 0.5
Lactate	7.1 ± 1.7	38.3 ± 3.5

**Table 2.** Anabolic demand of *Corynebacterium glutamicum* ATCC 21526 for intracellular metabolites in the stage of lysine production from glucose (left) and fructose (right). Experimental data are mean values of two parallel incubations on (i) [ $1\text{-}^{13}\text{C}$ ] labeled substrate and (ii) a 1:1 mixture of naturally labeled and [ $^{13}\text{C}_6$ ] substrate with deviation between the two incubations.

Precursor Demand <sup>*</sup> mmol (mol glucose) <sup>-1</sup>	Lysine production on glucose	Lysine production on fructose
Glucose 6-phosphate	11.09 ± 0.16	5.84 ± 0.05
Fructose 6-phosphate	3.84 ± 0.06	2.02 ± 0.02
Pentose 5-phosphate	47.50 ± 0.70	25.05 ± 0.21
Erythrose 4-phosphate	14.50 ± 0.22	7.64 ± 0.06
Glyceraldehyde 3-phosphate	6.98 ± 0.10	3.68 ± 0.03
3-Phosphoglycerate	59.95 ± 0.89	36.85 ± 0.31
Pyruvate/Phosphoenolpyruvate	107.80 ± 1.60	56.80 ± 0.48
$\alpha$ -Ketoglutarate	92.51 ± 1.37	48.73 ± 0.41
Oxaloacetate	48.91 ± 0.72	45.76 ± 0.38
Acetyl CoA	135.30 ± 2.00	71.25 ± 0.60
Diaminopimelate+Lysine <sup>**</sup>	18.83 ± 0.28	9.92 ± 0.08

<sup>\*</sup> The estimation of precursor demands was based on the experimental biomass yield obtained for each strain (Tab. 1) and the biomass composition previously measured for *C. glutamicum* (Marx, A., A. A. de Graaf, W. Wiechert, L. Eggeling and H. Sahm. 1996. Biotechnol. Bioeng. 49:111-129).

<sup>\*\*</sup> Diaminopimelate and lysine are regarded as separate anabolic precursors. This is due to the fact that anabolic fluxes from pyruvate and oxaloacetate into diaminopimelate (cell wall) and lysine (protein) contribute in addition to the flux of lysine secretion to the overall flux through the lysine biosynthetic pathway.

## EXAMPLE II: MANUAL INSPECTION OF $^{13}\text{C}$ -LABELING PATTERNS IN TRACER EXPERIMENTS

Relative mass isotopomer fractions of secreted lysine and trehalose were quantified with GC-MS. These mass isotopomer fractions are sensitive towards intracellular fluxes and therefore display fingerprints for the fluxome of the investigated biological system. As shown in Figure 2, labeling patterns of secreted lysine and trehalose differed significantly between glucose and fructose-grown cells of *C. glutamicum*. The differences were found for both applied tracer labelings and for both measured products. This indicates substantial differences in the carbon flux pattern depending on the applied carbon source. As previously shown, mass isotopomer fractions from two parallel cultivations of *C. glutamicum* on a mixture of [ $1\text{-}^{13}\text{C}$ ] and

[ $^{13}\text{C}_6$ ] glucose were almost identical (Wittmann, C., H. M. Kim and E. Heinzle. 2003. Metabolic flux analysis at miniaturized scale. submitted). Therefore, the differences observed can be clearly related to substrate specific differences in metabolic fluxes.

### 5                    **EXAMPLE III: ESTIMATION OF INTRACELLULAR FLUXES**

                  A central issue of the performed studies was the comparative investigation of intracellular fluxes of *C. glutamicum* during lysine production on glucose and fructose as carbon source, respectively. For this purpose, the experimental data obtained from the tracer experiments were used to calculate metabolic flux  
10       distributions for each substrate applying the flux estimation software as described above. The parameter estimation was carried out by minimizing the deviation between experimental and calculated mass isotopomer fractions. The performed approach utilized metabolite balancing during each step of the optimization. This included (i) stoichiometric data on product secretion (Table 2) and (ii) stoichiometric data on  
15       anabolic demand for biomass precursors (Table 3). The set of intracellular fluxes that gave the minimum deviation between experimental and simulated labeling patterns was taken as best estimate for the intracellular flux distribution. For both scenarios, identical flux distributions were obtained with multiple initialization values, suggesting that global minima were identified. Obviously, good agreement between experimentally  
20       determined and calculated mass isotopomer ratios was achieved (Table 4).

**Table 3:**

Relative mass isotopomer fractions of secreted lysine and trehalose of lysine producing *Corynebacterium glutamicum* ATCC 21526 cultivated on glucose and fructose, respectively. For both carbon sources two parallel tracer experiments on (i)  $[1-^{13}\text{C}]$  labeled and (ii) a 1:1 mixture of naturally  $^{13}\text{C}$  labeled and  $[^{13}\text{C}_6]$  labeled tracer substrate were carried out. Experimental GC/MS data (exp) and values predicted by the solution of the mathematical model corresponding to the optimized set of fluxes (calc).  $M_0$  denotes the relative amount of non-labelled mass isotopomer fraction,  $M_1$  the relative amount of the single labelled mass isotopomer fraction, and corresponding terms stand for higher labelling

	Lysine (on [1- <sup>13</sup> C] labeled substrate)					Trehalose (on [1- <sup>13</sup> C] labeled substrate)					Trehalose (on 50 % [ <sup>13</sup> C <sub>6</sub> ] labeled substrate)						
	M <sub>0</sub>	M <sub>1</sub>	M <sub>2</sub>	M <sub>3</sub>	M <sub>4</sub>	M <sub>0</sub>	M <sub>1</sub>	M <sub>2</sub>	M <sub>3</sub>	M <sub>4</sub>	M <sub>0</sub>	M <sub>1</sub>	M <sub>2</sub>	M <sub>3</sub>	M <sub>4</sub>	M <sub>5</sub>	M <sub>6</sub>
glucose																	
	0.234	0.360	0.247	0.110	0.037	0.110	0.551	0.216	0.094	0.023	0.271	0.114	0.087	0.115	0.069	0.066	0.279
exp																	
calc	0.242	0.355	0.245	0.110	0.037	0.114	0.549	0.212	0.094	0.023	0.268	0.113	0.085	0.113	0.068	0.064	0.289
fructose																	
	0.133	0.316	0.304	0.162	0.062	0.212	0.412	0.244	0.092	0.030	0.141	0.103	0.104	0.250	0.133	0.110	0.159
exp																	
calc	0.139	0.321	0.298	0.159	0.061	0.195	0.419	0.254	0.094	0.030	0.144	0.103	0.102	0.245	0.131	0.111	0.164

#### EXAMPLE IV: METABOLIC FLUXES ON FRUCTOSE AND GLUCOSE DURING LYSINE PRODUCTION

The obtained intracellular flux distributions for lysine-producing *C. glutamicum* on glucose and fructose are shown in Figs. (4, 5). Obviously, the intracellular fluxes differed tremendously depending on the carbon source applied. On glucose, 62 % of the carbon flux was directed towards the PPP, whereas only 36 % were channeled through the glycolytic chain (Fig. 4). Due to this a relatively high amount, 124 % NADPH was generated by the PPP enzymes glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. The situation on fructose was completely different (Fig. 5). The performed flux analysis revealed the *in vivo* activity of two PTS for uptake of fructose, whereby 92.3 % of fructose were taken up by fructose specific PTS<sub>Fructose</sub>. A comparably small fraction of 7.7 % of fructose was taken up by PTS<sub>Mannose</sub>. Thus, the majority of fructose entered the glycolysis at the level of fructose 1,6-bisphosphatase, whereas only a small fraction was channeled upstream at fructose 6-phosphate into the glycolytic chain. In comparison to glucose-grown cells, the PPP exhibited a dramatically reduced activity of only 14.4 %. Glucose 6-phosphate isomerase operated in opposite directions on the two carbon sources. In glucose-grown cells 36.2 % net flux were directed from glucose 6-phosphate to fructose 6-phosphate, whereas a backward net flux of 15.2 % was observed on fructose.

On fructose, the flux through glucose 6-phosphate isomerase and PPP was about twice as high as the flux through the PTS<sub>Mannose</sub>. However this was not due to a gluconeogenic flux of carbon from fructose 1,6 bisphosphatase to fructose 6-phosphate, which could have supplied extra carbon flux towards the PPP. In fact flux through fructose 1,6-bisphosphatase catalyzing this reaction was zero. The metabolic reactions responsible for the additional flux towards the PPP are the reversible enzymes transaldolase and transketolase in the PPP. About 3.5 % of this additional flux was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway. Moreover 4.2 % of flux was directed towards fructose 6-phosphate and the PPP by the action of transaldolase.

Depending on the carbon source, completely different flux patterns in lysine producing *C. glutamicum* were also observed around the pyruvate node (Figs. 4, 5). On glucose the flux into the lysine pathway was 30.0 %, whereas a reduced flux of 25.4 % was found on fructose. The elevated lysine yield on glucose compared to fructose is the major reason for this flux difference, but also the higher biomass yield resulting in a higher demand for diaminopimelate for cell wall synthesis and lysine for protein synthesis contributes to it. The anaplerotic flux on glucose was 44.5 % and thus markedly higher compared to the flux on fructose (33.5 %). This is mainly due to the higher demand for oxaloacetate for lysine production, but also to the higher anabolic

demands for oxaloacetate and 2-oxoglutarate on glucose. On the other hand, flux through pyruvate dehydrogenase was substantially lower on glucose (70.9 %) compared to fructose (95.2 %). This reduced carbon flux into the TCA cycle resulted in more than 30 % reduced fluxes through TCA cycle enzymes on glucose (Figs. 3, 4).

- 5 Statistical evaluation of the obtained fluxes by a Monte-Carlo approach was used to calculate 90 % confidence intervals for the determined flux parameters. As shown for various key fluxes in Table 5, the confidence intervals were generally narrow. As example the confidence interval for the flux through glucose 6-phosphate dehydrogenase was only 1.2 % for glucose-grown and 3.5 % for fructose-grown cells.
- 10 The chosen approach therefore allowed precise flux estimation. It can be concluded that the flux differences observed on glucose and fructose, respectively, are clearly caused by the applied carbon source.

- It has to be noticed that the mean specific substrate uptake of 1.93 mmol  $\text{g}^{-1} \text{h}^{-1}$  on fructose was slightly higher than that of 1.77 mmol  $\text{g}^{-1} \text{h}^{-1}$  found on glucose.
- 15 Due to this the absolute intracellular fluxes expressed in mmol  $\text{g}^{-1} \text{h}^{-1}$  are slightly increased in relation to glucose compared to the relative fluxes discussed above. The flux distributions of lysine producing *C. glutamicum* on fructose and glucose, respectively, are however so completely different, that all comparisons drawn above also hold for absolute carbon fluxes.

- 20 **Table 4:** Statistical evaluation of metabolic fluxes of lysine producing *Corynebacterium glutamicum* ATCC 21526 grown on fructose (left) and glucose (right) determined by  $^{13}\text{C}$  tracer studies with mass spectrometry and metabolite balancing: 90 % confidence intervals of key flux parameters were obtained by a Monte-Carlo approach including 100 independent parameter estimation runs for each substrate with statistically varied experimental data.
- 25

Flux parameter	Glucose	Fructose
<b>Net Flux</b>		[ 90.0 96.1]
fructose uptake by $\text{PTS}_{\text{Frc}}$	-	[ 3.9 10.0]
fructose uptake by $\text{PTS}_{\text{Mnn}}$	[ 35.7 36.8]	[ 13.4 16.9]
glucose 6-phosphate isomerase	[ 35.7 36.8]	-
phosphofructokinase	-	[ -2.1 3.4]
fructose 1,6-bisphosphatase	[ 73.7 73.8]	[ 91.7 92.9]
fructose 1,6-bisphosphatase aldolase	[ 62.5 63.7]	[ 12.6 16.1]
glucose 6-phosphate dehydrogenase	[ 19.4 19.8]	[ 3.6 4.1]
transaldolase	[ 19.4 19.8]	[ 3.6 4.1]
transketolase 1	[ 17.9 18.3]	[ 2.9 4.0]
transketolase 2	[ 158.1 164.5]	[ 163.3 174.6]
glyceraldehyde 3-phosphate dehydrogenase	[ 156.2 167.4]	[ 158.9 168.2]
pyruvate kinase	[ 69.5 72.5]	[ 87.1 102.3]
pyruvate dehydrogenase	[ 43.7 44.8]	[ 29.9 37.3]
pyruvate carboxylase	[ 51.2 54.8]	[ 76.5 91.5]



citrate synthase	[ 41.6 45.6]	[ 70.9 86.0]
isocitrate dehydrogenase	[ 29.6 30.3]	[ 21.8 29.2]
oxoglutarate dehydrogenase		
aspartokinase		
Flux Reversibility**	[ 4.5 5.1]	
glucose 6-phosphate isomerase	[ 4.3 4.9]	[ 14.5 18.2]
transaldolase	[ 0.0 0.0]	[ 0.0 0.1]
transketolase 1	[ 0.4 0.6]	[ 0.0 0.1]
transketolase 2		

\* The negative flux for the lower confidence boundary is equal to a positive flux in the reverse direction (through phosphofructokinase).

\*\* Flux reversibility is defined as ratio of back flux to net flux.

5

## Discussion of Examples I- IV:

### A. Substrate specific culture characteristics

- Cultivation of lysine producing *C. glutamicum* on fructose and on glucose, respectively, revealed that growth and product formation strongly depend on the carbon source applied. Significantly reduced yields of lysine and biomass on fructose were previously also reported for another strain of *C. glutamicum*, where lysine and biomass yield were 30 % and 20 % less, respectively, compared to glucose (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43).
- Cultivation of *C. glutamicum* and *C. melassecola* on fructose is linked to higher carbon dioxide production rates in comparison to glucose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Cocaign-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102; Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). This coincides with the elevated flux through the TCA cycle observed in the present work for this carbon source. Substrate specific differences were also observed for byproducts. The formation of trehalose was lower on fructose compared to glucose. This may be related to different entry points of glucose and fructose into glycolysis (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). Considering the uptake systems in *C. glutamicum*, utilization of glucose leads to the formation of the trehalose precursor glucose 6-phosphate, whereas fructose is converted into fructose 1,6-bisphosphatase and thus enters the central metabolism downstream from glucose 6-phosphate (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Cocaign-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). Other byproducts such as dihydroxyacetone, glycerol, and lactate were strongly increased, when fructose was applied as carbon source. From the viewpoint of lysine production, this is not desired, because a substantial fraction of carbon is withdrawn from the central metabolism into the formed byproducts. The specific substrate uptake on fructose ( $1.93 \text{ mmol g}^{-1} \text{ h}^{-1}$ ) was

higher than on glucose ( $1.77 \text{ mmol g}^{-1} \text{ h}^{-1}$ ). This result differs from a previous study on exponentially growing *C. melassecola* ATCC 17965 (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102), where similar specific uptake rates on fructose and glucose were observed. The higher uptake rate for fructose observed in our study might be due to the fact that the studied strains are different. *C. melassecola* and *C. glutamicum* are related species, but might differ in certain metabolic properties. The strain studied in the present work was previously derived by classical strain optimization. This could have introduced mutations influencing substrate uptake. Another explanation is the difference in cultivation conditions. Fructose might be more effectively utilized under conditions of limited growth and lysine production.

## B. Metabolic flux distributions

The obtained intracellular flux distributions for lysine-producing *C. glutamicum* on glucose and fructose revealed tremendous differences. Statistical evaluation of the obtained fluxes revealed narrow 90% confidence intervals, so that the observed flux differences can be clearly attributed to the applied carbon sources. One of the most remarkable differences concerns the flux partitioning between glycolysis and PPP. On glucose 62.3 % of carbon was channeled through the PPP. The predominance of the PPP of lysine-producing *C. glutamicum* on this substrate has been previously observed in different studies (Marx, A., A. A. de Graaf, W. Wiechert, L. Eggeling and H. Sahm. 1996. Biotechnol. Bioeng. 49:111-129; Wittmann, C. and E. Heinzle. 2001. Eur. J. Biochem. 268:2441-2455; Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). On fructose the flux into the PPP was reduced to 14.4 %. As identified by the performed metabolic flux analysis, this was mainly due to the unfavourable combination of the entry of fructose at the level of fructose 1,6-bisphosphatase and the inactivity of fructose 1,6 bisphosphatase. The observed inactivity of fructose 1,6 bisphosphatase agrees well with enzymatic measurements of *C. melassecola* ATCC 17965 during exponential growth on fructose and on glucose, respectively (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102).

Surprisingly, the flux through glucose 6-phosphate isomerase and PPP was about twice as high as the flux through the PTS<sub>Mannose</sub>, when *C. glutamicum* was cultivated on fructose. Due to the inactivity of fructose 1,6 bisphosphatase this was not caused by a gluconeogenic flux. In fact, *C. glutamicum* possesses an operating metabolic cycle via fructose 6-phosphate, glucose 6-phosphate, and ribose 5-phosphate. Additional flux into the PPP was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway, and by the action of transaldolase,

which redirected glyceraldehyde 3-phosphate back into the PPP, thus bypassing gluconeogenesis. This cycling activity may help the cell to overcome NADPH limitation on fructose. The drastically reduced flux arriving at glucose 6-phosphate for fructose-grown *C. glutamicum* might also explain the reduced formation of trehalose on this substrate (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). Glucose 6-phosphate isomerase operated in opposite directions depending on the carbon source. In glucose-grown net flux was directed from glucose 6-phosphate to fructose 6-phosphate, whereas an inverse net flux was observed on fructose. This underlines the importance of the reversibility of this enzyme for metabolic flexibility in *C. glutamicum*.

### C. NADPH metabolism

The following calculations provide a comparison of the NADPH metabolism of lysine producing *C. glutamicum* on fructose and glucose. The overall supply of NADPH was calculated from the estimated flux through glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and isocitrate dehydrogenase. On glucose, the PPP enzymes glucose 6-phosphate dehydrogenase (62.0 %) and glucose 6-phosphate dehydrogenase (62.0 %) supplied the major fraction of NADPH. Isocitrate dehydrogenase (52.9 %) contributed only to a minor extent. A completely different contribution of PPP and TCA cycle to NADPH supply was observed on fructose, where isocitrate dehydrogenase (83.3 %) was the major source for NADPH. Glucose 6-phosphate dehydrogenase (14.4 %) and glucose 6-phosphate dehydrogenase (14.4 %) produced much less NADPH on fructose. NADPH is required for growth and formation of lysine. The NADPH requirement for growth was calculated from a stoichiometric demand of 11.51 mmol NADPH (g biomass)<sup>-1</sup>, which was assumed to be identical for glucose and fructose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102), and the experimental biomass yield of the present work (Tab. 1). *C. glutamicum* consumed 62.3 % of NADPH for biomass production on glucose, which was much higher as compared to fructose as carbon source (32.8 %). The amount of NADPH required for product synthesis was determined from the estimated flux into lysine (Tab. 1) and the corresponding stoichiometric NADPH demand of 4 mol (mol lysine)<sup>-1</sup>. It was 112.4 % for lysine production from glucose and 97.6 % for lysine production from fructose. The overall NADPH supply on glucose was significantly higher (176.9 %) compared to fructose (112.1 %), which can be mainly attributed to the increased PPP flux on glucose. The NADPH balance was almost closed on glucose. In contrast a significant apparent deficiency for NADPH of 18.3 % was observed on fructose. This raises the question for enzymes catalyzing metabolic reactions that could supply NADPH in addition to the

above mentioned enzymes glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and isocitrate dehydrogenase. A likely candidate seems NADPH-dependent malic enzyme. Previously an increased specific activity of this enzyme was detected on fructose-grown *C. melassecola* in comparison to glucose-grown cells (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccain-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). However, the flux through this particular enzyme could not be resolved by the experimental setup in the present work. Assuming malic enzyme as missing NADPH generating enzyme, a flux of 18.3 % would be sufficient to supply the apparently missing NADPH. Detailed flux studies of *C. glutamicum* with glucose as carbon source revealed no significant activity of malic enzyme (Petersen, S., A. A. de Graaf, L. Eggeling, M. Möllney, W. Wiechert and H. Sahm. 2000. J. Biol. Chem. 275:35932-35941). The situation on fructose might however be coupled to elevated *in vivo* activity of this enzyme.

#### 15 D. NADH metabolism

On fructose *C. glutamicum* revealed increased activity of NADH forming enzymes. 421.2 % NADH were formed on fructose by glyceraldehyde 3-phosphate dehydrogenase, pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, and malate dehydrogenase. On glucose the NADH production was only 322.4 %. Additionally, the anabolic NADH demand was significantly lower on fructose than on glucose. The significantly enhanced NADH production coupled to a reduced metabolic demand could lead to an increased NADH/NAD ratio. For *C. melassecola* it was previously shown that fructose leads to increased NADH/NAD ratio compared to glucose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccain-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). This raises the question for NADH regenerating mechanisms during lysine production on fructose. Fructose-grown cells exhibited an enhanced secretion of dihydroxyacetone, glycerol, and lactate. The increased formation of dihydroxyacetone and glycerol could be due a higher NADH/NAD ratio. NADH was previously shown to inhibit glyceraldehyde dehydrogenase, so that overflow of dihydroxyacetone and glycerol might be related to a reduction of the flux capacity of this enzyme. The reduction of dihydroxyacetone to glycerol could additionally be favored by the high NADH/NAD ratio and thus contribute to regeneration of excess NADH. The NADH demanding lactate formation from pyruvate could have a similar background as the production of glycerol. In comparison to exponential growth, NADH excess under lysine producing conditions, characterized by relatively high TCA cycle activity and reduced biomass yield, might be even higher.

### E. Potential targets for optimization of lysine-producing *C. glutamicum* on fructose

Based on the obtained flux patterns, several potential targets for the optimization of lysine production by *C. glutamicum* on fructose can be formulated. A central point is the supply of NADPH. Fructose 1,6 biphosphatase is one target for increasing the supply of NADPH. Deregulation, *e.g.*, amplification of its activity leads to a higher flux through the PPP, resulting in increased NADPH generation and increased lysine yield. An increase of the flux through the PPP via amplification of fructose 1,6-bisphosphatase is also be beneficial for aromatic amino acid production (Ikeda, M. 2003. Adv. Biochem. Eng. Biotechnol. 79: 1-36). The inactivity of fructose 1,6-bisphosphatase during growth on fructose is detrimental from the viewpoint of lysine production but not surprising, because this gluconeogenic enzyme is not required during growth on sugars and probably suppressed. In prokaryotes, this enzyme is under efficient metabolic control by *e.g.* fructose 1,6-bisphosphatase, fructose-2,6 bisphosphatase, metal ions and AMP (Skrypal, I. G. and O. V. Iastrebova. 2002. Mikrobiol Z. 64:82-94). It is known that *C. glutamicum* can grow on acetate (Wendisch, V. F., A. A. de Graaf, H. Sahm H. and B. Eikmans. 2000. J. Bacteriol. 182:3088-3096), where this enzyme is essential to maintain gluconeogenesis. Another potential target to increase the flux through the PPP is the PTS for fructose uptake. Modification of flux partitioning between PTS<sub>Fructose</sub> and PTS<sub>Mannose</sub> could yield a higher proportion of fructose, which enters at the level of fructose 6-phosphate and thus also lead to an increased PPP flux. Additionally amplification of malic enzyme that probably contributes significantly to NADPH supply on fructose could be an interesting target.

Another bottleneck comprises the strong secretion of dihydroxyacetone, glycerol, and lactate. The formation of dihydroxyacetone and glycerol could be blocked by deregulation, *e.g.*, deletion, of the corresponding enzymes. The conversion of dihydroxyacetone phosphate to dihydroxyacetone could be catalyzed by a corresponding phosphatase. A dihydroxyacetone phosphatase has however yet not been annotated in *C. glutamicum* (see the National Center for Biotechnology Information (NCBI) Taxonomy website: <http://www3.ncbi.nlm.nih.gov/Taxonomy/>). This reaction may be also catalyzed by a kinase, *e.g.*, lactate dehydrogenase. Currently two entries in the genome data base of *C. glutamicum* relate to dihydroxyacetone kinase (see the National Center for Biotechnology Information (NCBI) Taxonomy website: <http://www3.ncbi.nlm.nih.gov/Taxonomy/>).

In one embodiment, deregulation of one or more of the above genes in combination is useful in the production of a fine chemical, *e.g.*, lysine.

Lactate secretion can also be avoided by deregulation, *e.g.*, knockout of lactate dehydrogenase. Since glycerol and lactate formation could be important for NADH regeneration, negative effects on the overall performance of the organism can however not be excluded. In case carbon flux through the lower glycolytic chain is limited by the capacity of glyceraldehyde 3-phosphate dehydrogenase as previously speculated (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. *Eur. J. Biochem.* 254:96-102), the suppression of dihydroxyacetone and glycerol production could eventually lead to an activation of fructose 1,6 bisphosphatase and a redirection of carbon flux through the PPP. It should be noticed that dihydroxyacetone is not reutilized during the cultivation of *C. glutamicum* and thus displays wasted carbon with respect to product synthesis, whereas this is not the case for lactate (Coccagn-Bousquet, M. and N. D. Lindley. 1995. *Enz. Microbiol. Technol.* 17:260-267).

In addition, sucrose is also useful as carbon source for lysine production by *C. glutamicum*, *e.g.*, used in conjunction with the methods of the invention. Sucrose is the major carbon source in molasses. As shown previously, the fructose unit of sucrose enters glycolysis at the level of fructose 1,6-bisphosphatase (Dominguez, H. and N. D. Lindley. 1996. *Appl. Environ. Microbiol.* 62:3878-3880). Therefore this part of the sucrose molecule - assuming an inactive fructose 1,6-bisphosphatase - probably does not enter into the PPP, so that NADPH supply in lysine producing strains could be limited.

#### EXAMPLE V: CONSTRUCTION OF PLASMID PCIS LYSC

The first step of strain construction calls for an allelic replacement of the lysC wild-type gene in *C. glutamicum* ATCC13032. In it, a nucleotide replacement in the lysC gene is carried out, so that, the resulting protein, the amino acid Thr in position 311 is replaced by an Ile. Starting from the chromosomal DNA from ATCC13032 as template for a PCR reaction and using the oligonucleotide primers SEQ ID NO:3 and SEQ ID NO:4, lysC is amplified by use of the Pfu Turbo PCR system (Stratagene USA) in accordance with the instructions of the manufacturer. Chromosomal DNA from *C. glutamicum* ATCC 13032 is prepared according to Tauch et al. (1995) *Plasmid* 33:168-179 or Eikmanns et al. (1994) *Microbiology* 140:1817-1828. The amplified fragment is flanked at its 5' end by a SalI restriction cut and at its 3' end by a MluI restriction cut. Prior to the cloning, the amplified fragment is digested by these two restriction enzymes and purified using the GFX™ PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg).

SEQ ID NO:3

5'-GAGAGAGAGACGCGTCCCAGTGGCTGAGACGCATC-3'

SEQ ID NO:4

5 5'-CTCTCTCTGTCGACGAATTCAATCTTACGGCCTG-3'

The obtained polynucleotide is cloned through the SalI and MluI restriction cuts in pCLIK5 MCS with integrated SacB, referred to in the following as pCIS (SEQ ID NO: 5) and transformed in *E. coli* XL-1 blue. A selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190). The plasmid is isolated and the expected nucleotide sequence is confirmed by sequencing. The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Quiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied Biosystems, Weiterstadt) and analyzed. The obtained plasmid pCIS lysC is listed as SEQ ID NO:6.

#### EXAMPLE VI: MUTAGENESIS OF THE LYSC GENE FROM *C. GLUTAMICUM*

The targeted mutagenesis of the lysC gene from *C. glutamicum* is carried out using the QuickChange Kit (Company: Stratagene/USA) in accordance with the instructions of the manufacturer. The mutagenesis is carried out in the plasmid pCIS lysC, SEQ ID NO:6. The following oligonucleotide primers are synthesized for the replacement of thr 311 by 311 ile by use of the QuickChange method (Stratagene):

SEQ ID NO:7

5'-CGGCACCACCGACATCATCTTCACCTGCCCTCGTTCCG-3'

30 SEQ ID NO:8

5'-CGGAACGAGGGCAGGTGAAGATGATGTCGGTGGTGCCG-3'

The use of these oligonucleotide primers in the QuickChange reaction leads, in the lysC gene SEQ ID NO:9, to the replacement of the nucleotide in position 932 (from C to T). The resulting amino acid replacement Thr311Ile in the lysC gene is confirmed, after transformation in *E. coli* XL1-blue and plasmid preparation, by [a] sequencing reactions. The plasmid is given the designation pCIS lysC thr311 ile and is listed as SEQ ID NO:10.

The plasmid pCIS lysC thr311ile is transformed in *C. glutamicum* ATCC13032 by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the lysC locus of individual transformants is checked using standard methods by Southern blot and hybridization, as described in 5 Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor. It is thereby established that the transformants involved are those that have integrated the transformed plasmid by homologous recombination at the lysC locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a 10 saccharose CM agar medium (10% saccharose) and incubated at 30°C for 24 hours. Because the sacB gene contained in the vector pCIS lysC thr311ile converts saccharose into a toxic product, only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type lysC gene and the mutated gene lysC thr311ile. During the homologous recombination, either the wild- 15 type gene or the mutated gene together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.

Growing colonies are picked and examined for a kanamycin-sensitive phenotype. Clones with deleted SacB gene must simultaneously show kanamycin-sensitive growth behavior. Such kanamycin-sensitive clones are investigated in a 20 shaking flask for their lysine productivity (see Example 6). For comparison, the non-treated *C. glutamicum* ATCC13032 is taken. Clones with an elevated lysine production in comparison to the control are selected, chromosomal DNA are recovered, and the corresponding region of the lysC gene is amplified by a PCR reaction and sequenced. One such clone with the property of elevated lysine synthesis and detected mutation in 25 lysC at position 932 is designated as ATCC13032 lysCfbr.

#### **EXAMPLE VII: PREPARATION OF THE PLASMID PK19 MOB SACB DELTA LACTATE DEHYDROGENASE**

30 Chromosomal DNA from *C. glutamicum* ATCC 13032 is prepared according to Tauch et al. (1995) Plasmid 33:168-179 or Eikmanns et al. (1994) Microbiology 140:1817-1828. With the oligonucleotide primers SEQ ID NO:11 and SEQ ID NO:12, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), the gene of lactate dehydrogenase with flanking regions is amplified by use of the 35 polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.



SEQ ID NO:11

5'-CTAGCTAGCCATTGTCCTTCTGGCAGT-3'

SEQ ID NO:12

5 5'-CTAGTCTAGACGCTCGTGTTCCTTTAGA-3'

The obtained DNA fragment of approximately 2.0 kb size is purified using the GFX™ PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer. Following this, it is cleaved using the restriction enzymes NheI and XbaI (Roche Diagnostics, Mannheim) and the DNA

10 fragment is purified using the GFX™ PCR DNA and Gel Band Purification Kit.

The plasmid pK19 mob sacB, SEQ ID NO:13, is also cut with the restriction enzymes NheI and XbaI and a fragment of 5.5 kb size is isolated, after electrophoretic separation, by use of the GFX™ PCR DNA and Gel Band Purification Kit.

The vector fragment is ligated together with the PCR fragment by use of the

15 Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer and the ligation batch is transformed in competent E. coli XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)). A selection for plasmid-carrying cells is accomplished by plating out on

20 kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190).

The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied

25 Biosystems, Weiterstadt) and analyzed.

The resulting plasmid is designated as pK19 lactate dehydrogenase (SEQ ID NO:14).

The plasmid pK19 lactate dehydrogenase is subsequently cut with the restriction enzymes EcoRI and BglI (Roche Diagnostics, Mannheim) and a fragment of 6.7 kb size

30 is isolated, after electrophoretic separation, by use of the GFX™ PCR DNA and Gel Band Purification Kit. After a treatment of this fragment with the Klenow enzyme in accordance with the instructions of the manufacturer, the religation took place by use of the Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer. The ligation batch is transformed in competent E. coli

35 XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)). A selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190).

The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Quiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions were separated by means of ABI Prism 377 (PE Applied Biosystems, Weiterstadt) and analyzed.

The resulting plasmid pK19 delta lactate dehydrogenase is listed as SEQ ID NO:15.

### EXAMPLE VIII: PRODUCTION OF LYSINE

The plasmid pk19 delta lactate dehydrogenase is transformed in *C. glutamicum* ATCC13032  $lysC^{thr}$  by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the lactate dehydrogenase gene locus of individual transformants is checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor. It is thereby established that the transformants involve those that have integrated the transformed plasmid by homologous recombination at the lactate dehydrogenase gene locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a saccharose CM agar medium (10% saccharose) and incubated at 30°C for 24 hours. Because the sacB gene contained in the vector pK19 delta lactate dehydrogenase converts saccharose into a toxic product, only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type lactate dehydrogenase gene and the shortened gene. During the homologous recombination, either the wild-type gene or the shortened gene together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.

Growing colonies are picked and examined for a kanamycin-sensitive phenotype. Clones with deleted SacB gene must simultaneously show kanamycin-sensitive growth behavior. Whether the desired replacement of the natural gene by the shortened gene had also taken place is checked by means of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.. For this analysis, chromosomal DNA from the starting strain and the resulting clones is isolated. To this end, the respective clones were removed from the agar plate with a toothpick and suspended in 100  $\mu$ L of H<sub>2</sub>O and boiled up for 10 min at 95°C. In each case, 10  $\mu$ L of the resulting solution is used as template in the PCR. Used as primers are the oligonucleotides CK360 and CK361. A PCR product larger than in the case of a shortened gene is expected in the batch with the DNA of the starting strain owing to the

BGI-159PC

choice of the oligonucleotide. A positive clone is designated as ATCC13032 Psod lysC<sup>fbr</sup> delta lactate dehydrogenase.

In order to investigate the effect of the delta lactate dehydrogenase construct on the lysine production, the strains ATCC13032, ATCC13032 lysC<sup>fbr</sup>, and  
 5 ATCC13032 lysC<sup>fbr</sup> delta lactate dehydrogenase are cultivated on CM plates (10.0 g/L D-glucose, 2.5 g/L NaCl, 2.0 g/L urea, 10.0 g/L bacto pepton (Difco), 5.0 g/L yeast extract (Difco), 5.0 g/L beef extract (Difco), 22.0 g/L agar (Difco), autoclaved (20 min. 121°C)) for 2 days at 30°C. Subsequently, the cells are scraped off the plate and resuspended in saline. For the main culture, 10 mL of medium I and 0.5 g of autoclaved  
 10 CaCO<sub>3</sub> (Riedel de Haen) were inoculated in a 100 mL Erlenmeyer flask with the cell suspension up to an OD<sub>600</sub> of 1.5 and incubated for 39 h on a [shaking incubator] of the type Infors AJ118 (Company: Infors, Bottmingen, Switzerland) at 220 rpm. Subsequently, the concentration of the lysine that separated out in the medium is determined.

15

Medium I:

	40 g/L	saccharose
	60 g/L	Molasses (calculated with respect to 100% sugar content)
	10 g/L	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>
20	0.4 g/L	MgSO <sub>4</sub> *7H <sub>2</sub> O
	0.6 g/L	KH <sub>2</sub> PO <sub>4</sub>
	0.3 mg/L	thiamine*HCl
	1 mg/L	biotin (from a 1 mg/mL sterile-filtered stock solution that is adjusted with NH <sub>4</sub> OH to pH 8.0)
25	2 mg/L	FeSO <sub>4</sub>
	2 mg/L	MnSO <sub>4</sub>

adjusted with NH<sub>4</sub>OH to pH 7.8, autoclaved (121°C, 20 min).

in addition, vitamin B12 (hydroxycobalamin Sigma Chemicals) from a stock solution (200 µg/mL, sterile-filtered) is added up to a final concentration of 100 µg/L.

30

The determination of the amino acid concentration is conducted by means of high pressure liquid chromatography according to Agilent on an Agilent 1100 Series LC System HPLC. A precolumn derivatization with ortho-phthalaldehyde permits the quantification of the amino acids that are formed; the separation of the amino acid mixture takes place on a Hypersil AA column (Agilent).

35

Moreover, the concentration of lactate is determined using an enzymatic test.

**Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the

5 following claims.

What is claimed:

1. A method for increasing metabolic flux through the pentose phosphate pathway in a microorganism comprising culturing a microorganism comprising a gene which is deregulated under conditions such that metabolic flux through the pentose phosphate pathway is increased.
2. The method of claim 1, wherein fructose or sucrose is used as a carbon source.
3. The method of claim 1, wherein fructose is used as a carbon source.
4. The method of claim 1, wherein the gene is lactate dehydrogenase.
5. The method of claim 4, wherein the lactate dehydrogenase gene is derived from *Corynebacterium*.
6. The method of claim 4, wherein the lactate dehydrogenase gene is underexpressed.
7. The method of claim 1, wherein the gene encodes lactate dehydrogenase.
8. The method of claim 7, wherein lactate dehydrogenase has decreased activity.
9. The method of claim 1, wherein the microorganism is a Gram positive microorganism.
10. The method of claim 1, wherein the microorganism belongs to the genus *Corynebacterium*.
11. The method of claim 10, wherein the microorganism is *Corynebacterium glutamicum*.
12. The method of claim 1, wherein the microorganism is fermented to produce a fine chemical.
13. The method of claim 1, wherein the microorganism further comprises one or more additional deregulated genes.

14. A method for producing a fine chemical comprising:
  - a) culturing a microorganism in which lactate dehydrogenase is deregulated;  
and
  - b) accumulating the fine chemical in the medium or in the cells of the  
microorganisms, thereby producing a fine chemical.
15. A method for producing a fine chemical comprising culturing a microorganism  
in which at least one pentose phosphate biosynthetic pathway gene or enzyme is  
deregulated under conditions such that the fine chemical is produced.
16. The method of claim 15, wherein said biosynthetic gene is lactate  
dehydrogenase.
17. The method of claim 15, wherein said biosynthetic enzyme is lactate  
dehydrogenase.
18. The method of claim 16, wherein lactate dehydrogenase expression is decreased.
19. The method of claim 17, wherein lactate dehydrogenase activity is decreased.
20. The method of claim 14, further comprising recovering the fine chemical.
21. The method of claim 14 or 15, wherein the microorganism is a Gram positive  
microorganism.
22. The method of claim 14 or 15, wherein the microorganism belongs to the genus  
*Corynebacterium*.
23. The method of claim 22, wherein the microorganism is *Corynebacterium*  
*glutamicum*.
24. The method of claim 14, wherein lactate dehydrogenase expression is decreased.
25. The method of claim 14, wherein lactate dehydrogenase activity is decreased.
26. The method of claim 14 or 15, wherein the fine chemical is lysine.
27. The method of claim 26, wherein lysine is produced at a yield of at least 100 g/L.
28. The method of claim 26, wherein lysine is produced at a yield of at least 150 g/L.
29. The method of claim 14 or 15, wherein fructose or sucrose is used as a carbon  
source.

30. The method of claim 14 or 15, wherein fructose is used as a carbon source.
31. The method of claim 14 or 16, wherein lactate dehydrogenase comprises the  
5 nucleotide sequence of SEQ ID NO:1.
32. The method of claim 14 or 16, wherein lactate dehydrogenase encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 10 33. A recombinant microorganism which has a deregulated pentose phosphate biosynthesis pathway.
34. A recombinant microorganism comprising a deregulated pentose phosphate biosynthesis gene.
- 15 35. The recombinant microorganism of claim 34, wherein said deregulated gene is lactate dehydrogenase.
36. The recombinant microorganism of claim 35, wherein lactate dehydrogenase  
20 expression is decreased.
37. The recombinant microorganism of claim 35, wherein said lactate dehydrogenase gene encodes a lactate dehydrogenase protein having decreased activity.
- 25 38. The recombinant microorganism of claim 34, wherein the microorganism belongs to the genus *Corynebacterium*.
39. The recombinant microorganism of claim 38, wherein the microorganism is  
30 *Corynebacterium glutamicum*.

## METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

5

### Abstract of the Disclosure

The present invention features methods of increasing the production of a fine chemical, *e.g.*, lysine from a microorganism, *e.g.*, *Corynebacterium* by way of deregulating an enzyme encoding gene, *i.e.*, lactate dehydrogenase. In a preferred embodiment, the invention provides methods of increasing the production of lysine in  
10 *Corynebacterium glutamicum* by way of increasing the expression of lactate dehydrogenase activity. The invention also provides a novel process for the production of lysine by way of regulating carbon flux towards oxaloacetate (OAA). In a preferred embodiment, the invention provides methods for the production of lysine by way of  
15 utilizing fructose or sucrose as a carbon source.

15







FIGURE 1

**FIGURE 2**




FIGURE 3





FIGURE 4



## FIGURE 5

## SEQUENCE LISTING

<110> BASF and University Saarbrucken et al.

<120> METHODS FOR THE PREPARATION OF A FINE  
CHEMICAL BY FERMENTATION

<130> BGI-160PC

<160> 15

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1660

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (301)...(1563)

<400> 1

```

tcggcaccct ctggggtagc gtcaacgcaa tcctcggaac cgtcatcgca gaaaacttcg 60
cacctgaggt ccgctacacc ggcgctaccc tggggtacca agtcggagca gcactcttcg 120
gcggtaccgc acccattatc gcagcatggc tgttcgaaat ctccggcgga caatgggtggc 180
caatcgccgt ctacgtcgct gcatgttgcc ttctctctgt gatcgccctg ttcttcaccc 240
aacgcgtcgc gcaccaagag aactaaaatc taagtataaac ccctccgaaa ggaaccaccc 300
atg gtg aaa cgt caa ctg ccc aac ccc gca gaa cta ctc gaa ctc atg 348
Met Val Lys Arg Gln Leu Pro Asn Pro Ala Glu Leu Leu Glu Leu Met
1 5 10 15

```

```

aag ttc aaa aag cca gag ctc aac ggc aag aaa cga cgc cta gac tcc 396
Lys Phe Lys Lys Pro Glu Leu Asn Gly Lys Lys Arg Arg Leu Asp Ser
20 25 30

```

```

gcg ctc acc atc tac gac ctg cgt aaa att gct aaa cga cgc acc cca 444
Ala Leu Thr Ile Tyr Asp Leu Arg Lys Ile Ala Lys Arg Arg Thr Pro
35 40 45

```

```

gct gcc gcg ttc gac tac acc gac ggc gca gcc gag gcc gaa ctc tca 492
Ala Ala Ala Phe Asp Tyr Thr Asp Gly Ala Ala Glu Ala Glu Leu Ser
50 55 60

```

```

atc aca cgc gca cgt gaa gca ttc gaa aac atc gaa ttc cac cca gac 540
Ile Thr Arg Ala Arg Glu Ala Phe Glu Asn Ile Glu Phe His Pro Asp
65 70 75 80

```

```

atc ctc aag cct gca gaa cac gta gac acc acc acc caa atc ctg ggc 588
Ile Leu Lys Pro Ala Glu His Val Asp Thr Thr Thr Gln Ile Leu Gly
85 90 95

```

```

gga acc tcc tcc atg cca ttc ggc atc gca cca acc ggc ttc acc cgc 636
Gly Thr Ser Ser Met Pro Phe Gly Ile Ala Pro Thr Gly Phe Thr Arg
100 105 110

```

## BGI-160US

ctc atg cag acc gaa ggt gaa atc gca ggt gcc gga gct gca ggc gct 684  
 Leu Met Gln Thr Glu Gly Glu Ile Ala Gly Ala Gly Ala Ala Gly Ala  
 115 120 125

gca gga att cct ttc acc ctg tcc acc ctg ggc act acc tcc atc gaa 732  
 Ala Gly Ile Pro Phe Thr Leu Ser Thr Leu Gly Thr Thr Ser Ile Glu  
 130 135 140

gac gtc aag gcc acc aac ccc aac ggc cga aac tgg ttc cag ctc tac 780  
 Asp Val Lys Ala Thr Asn Pro Asn Gly Arg Asn Trp Phe Gln Leu Tyr  
 145 150 155 160

gtc atg cgc gac cgc gaa atc tcc tac ggc ctc gtc gaa cgc gca gcc 828  
 Val Met Arg Asp Arg Glu Ile Ser Tyr Gly Leu Val Glu Arg Ala Ala  
 165 170 175

aaa gca gga ttc gac acc ctg atg ttc acc gtg gat acc ccc atc gcc 876  
 Lys Ala Gly Phe Asp Thr Leu Met Phe Thr Val Asp Thr Pro Ile Ala  
 180 185 190

ggc tac cgc atc cgc gat tcc cgc aac gga ttc tcc atc ccg cca cag 924  
 Gly Tyr Arg Ile Arg Asp Ser Arg Asn Gly Phe Ser Ile Pro Pro Gln  
 195 200 205

ctg acc cca tcc acc gtg ctc aat gca atc cca cgc cca tgg tgg tgg 972  
 Leu Thr Pro Ser Thr Val Leu Asn Ala Ile Pro Arg Pro Trp Trp Trp  
 210 215 220

atc gac ttc ctg acc acc cca acc ctt gag ttc gca tcc ctt tcc tcg 1020  
 Ile Asp Phe Leu Thr Thr Pro Thr Leu Glu Phe Ala Ser Leu Ser Ser  
 225 230 235 240

acc ggc gga acc gtg ggc gac ctc ctc aac tcc gcg atg gat ccc acc 1068  
 Thr Gly Gly Thr Val Gly Asp Leu Leu Asn Ser Ala Met Asp Pro Thr  
 245 250 255

att tct tac gaa gac ctc aag gtc atc cgt gaa atg tgg cca ggc aag 1116  
 Ile Ser Tyr Glu Asp Leu Lys Val Ile Arg Glu Met Trp Pro Gly Lys  
 260 265 270

ctc gta gtc aag ggt gtc cag aac gtt gaa gac tcc gtc aaa ctc ctc 1164  
 Leu Val Val Lys Gly Val Gln Asn Val Glu Asp Ser Val Lys Leu Leu  
 275 280 285

gac caa ggc gtc gac ggc ctc atc ctc tcc aac cac ggt ggc cgt caa 1212  
 Asp Gln Gly Val Asp Gly Leu Ile Leu Ser Asn His Gly Gly Arg Gln  
 290 295 300

ctc gac cgc gca cca gtc cca ttc cac ctc ctg cca cag gta cgc aag 1260  
 Leu Asp Arg Ala Pro Val Pro Phe His Leu Leu Pro Gln Val Arg Lys  
 305 310 315 320

gaa gtc gga tct gaa cca acc atc atg atc gac acc ggc atc atg aac 1308  
 Glu Val Gly Ser Glu-Pro-Thr-Ile Met Ile Asp Thr Gly Ile Met Asn  
 325 330 335

ggc gcc gac atc gtc gca gcc gta gcc atg ggc gct gac ttc acc ctc 1356  
 Gly Ala Asp Ile Val Ala Ala Val Ala Met Gly Ala Asp Phe Thr Leu  
 340 345 350

## BGI-160US

atc ggt cgt gcc tac ctc tac gga ctc atg gcc gga ggc cgc gaa ggc 1404  
 Ile Gly Arg Ala Tyr Leu Tyr Gly Leu Met Ala Gly Gly Arg Glu Gly  
 355 360 365  
 gtc gac cgc acc atc gcc att ctc cgc agc gag atc acc cgc acc atg 1452  
 Val Asp Arg Thr Ile Ala Ile Leu Arg Ser Glu Ile Thr Arg Thr Met  
 370 375 380  
 gct ctc ctc ggt gtt tcc tcc ctc gaa gaa ctc gag cca cgc cac gtc 1500  
 Ala Leu Leu Gly Val Ser Ser Leu Glu Glu Leu Glu Pro Arg His Val  
 385 390 395 400  
 acc cag ctg gcc agc atg gtt cca gtt tct gac gca act cgt tct gca 1548  
 Thr Gln Leu Ala Lys Met Val Pro Val Ser Asp Ala Thr Arg Ser Ala  
 405 410 415  
 gcg gcg gag att taa aagtttctct ccttagctat taaaagggtgc ccatccgttt 1603  
 Ala Ala Glu Ile \*  
 420  
 ggatgggcac cttctcgttt cttgcaatcg gcatattcag tcaaaaaatg ttgaaat 1660

<210> 2  
 <211> 420  
 <212> PRT  
 <213> Corynebacterium glutamicum

<400> 2  
 Met Val Lys Arg Gln Leu Pro Asn Pro Ala Glu Leu Leu Glu Leu Met  
 1 5 10 15  
 Lys Phe Lys Lys Pro Glu Leu Asn Gly Lys Lys Arg Arg Leu Asp Ser  
 20 25 30  
 Ala Leu Thr Ile Tyr Asp Leu Arg Lys Ile Ala Lys Arg Arg Thr Pro  
 35 40 45  
 Ala Ala Ala Phe Asp Tyr Thr Asp Gly Ala Ala Glu Ala Glu Leu Ser  
 50 55 60  
 Ile Thr Arg Ala Arg Glu Ala Phe Glu Asn Ile Glu Phe His Pro Asp  
 65 70 75 80  
 Ile Leu Lys Pro Ala Glu His Val Asp Thr Thr Thr Gln Ile Leu Gly  
 85 90 95  
 Gly Thr Ser Ser Met Pro Phe Gly Ile Ala Pro Thr Gly Phe Thr Arg  
 100 105 110  
 Leu Met Gln Thr Glu Gly Glu Ile Ala Gly Ala Gly Ala Ala Gly Ala  
 115 120 125  
 Ala Gly Ile Pro Phe Thr Leu Ser Thr Leu Gly Thr Thr Ser Ile Glu  
 130 135 140  
 Asp Val Lys Ala Thr Asn Pro Asn Gly Arg Asn Trp Phe Gln Leu Tyr  
 145 150 155 160  
 Val Met Arg Asp Arg Glu Ile Ser Tyr Gly Leu Val Glu Arg Ala Ala  
 165 170 175  
 Lys Ala Gly Phe Asp Thr Leu Met Phe Thr Val Asp Thr Pro Ile Ala  
 180 185 190  
 Gly Tyr Arg Ile Arg Asp Ser Arg Asn Gly Phe Ser Ile Pro Pro Gln  
 195 200 205  
 Leu Thr Pro Ser Thr Val Leu Asn Ala Ile Pro Arg Pro Trp Trp Trp  
 210 215 220  
 Ile Asp Phe Leu Thr Thr Pro Thr Leu Glu Phe Ala Ser Leu Ser Ser  
 225 230 235 240  
 Thr Gly Gly Thr Val Gly Asp Leu Leu Asn Ser Ala Met Asp Pro Thr  
 245 250 255



Ile Ser Tyr Glu Asp Leu Lys Val Ile Arg Glu Met Trp Pro Gly Lys  
 260 265 270  
 Leu Val Val Lys Gly Val Gln Asn Val Glu Asp Ser Val Lys Leu Leu  
 275 280 285  
 Asp Gln Gly Val Asp Gly Leu Ile Leu Ser Asn His Gly Gly Arg Gln  
 290 295 300  
 Leu Asp Arg Ala Pro Val Pro Phe His Leu Leu Pro Gln Val Arg Lys  
 305 310 315 320  
 Glu Val Gly Ser Glu Pro Thr Ile Met Ile Asp Thr Gly Ile Met Asn  
 325 330 335  
 Gly Ala Asp Ile Val Ala Ala Val Ala Met Gly Ala Asp Phe Thr Leu  
 340 345 350  
 Ile Gly Arg Ala Tyr Leu Tyr Gly Leu Met Ala Gly Gly Arg Glu Gly  
 355 360 365  
 Val Asp Arg Thr Ile Ala Ile Leu Arg Ser Glu Ile Thr Arg Thr Met  
 370 375 380  
 Ala Leu Leu Gly Val Ser Ser Leu Glu Glu Leu Glu Pro Arg His Val  
 385 390 395 400  
 Thr Gln Leu Ala Lys Met Val Pro Val Ser Asp Ala Thr Arg Ser Ala  
 405 410 415  
 Ala Ala Glu Ile  
 420

<210> 3  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 3  
 gagagagaga cgcgtcccag tggctgagac gcac

35

<210> 4  
 <211> 34  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 4  
 ctctctctgt cgacgaattc aatcttacgg cctg

34

<210> 5  
 <211> 4323  
 <212> DNA  
 <213> Corynebacterium glutamicum

<400> 5  
 tcgagaggcc tgacgtcggg cccggtacca cgcgtcatat gactagttcg gacctagggg 60  
 tatcgtcgac atcgtatgctc ttctgctgta attacaatt gggatcctct agaccgaggg 120  
 tttaaatcgc tagcgggctg cttaaaggga cggaacacgt agaaagccag tccgcagaaa 180  
 cgggtgctgac cccggatgaa tgtcagctac tgggctatct ggacaaggga aaacgcaagc 240  
 gcaaagagaa agcaggtagc ttgcagtggg cttacatggc gatagctaga ctgggcgggt 300  
 ttatggacag caagcgaacc ggaattgcca gctggggcgc cctctggtaa ggttgggaag 360  
 ccctgcaaag taaactggat ggctttcttg ccgccaagga tctgatggcg caggggatca 420  
 agatctgatc aagagacagg atgaggatcg tttcgcata ttgaacaaga tggattgcac 480  
 gcaggttctc cggccgcttg ggtggagagg ctattcggct atgactgggc acaacagaca 540

## BGI-160US

```

atcggtgct ctgatgccgc cgtgttccgg ctgtcagcgc aggggcgcgc ggttcttttt 600
gtcaagaccg acctgtccgg tgccctgaat gaactgcagg acgaggcagc gcggtatcgc 660
tggttgccca cgacgggcgt tccttgccga gctgtgctcg acgttgtcac tgaagcggga 720
agggactggc tgctattggg cgaagtgcgc gggcaggatc tcctgtcatc tcaccttgct 780
cctgccgaga aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgatccg 840
gctacctgcc cattcgacca ccaagcgaaa catcgcacgc agcagcacgc tactcggatg 900
gaagccggtc ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc 960
gaactgttcg ccaggctcaa ggccgcgcgc cccgacggcg aggatctcgt cgtgacccat 1020
ggcgatgcct gcttgccgaa tatcatgggt gaaaatggcc gcttttctgg attcatcgac 1080
tgtggccggc tgggtgtggc ggaccgctat caggacatag cgttggctac ccgtgatatt 1140
gctgaagagc ttggcggcga atgggctgac cgttctctcg tgctttacgg tatcgccgct 1200
cccgatccgc agcgcacgc cttctatcgc cttcttgacg agttctctcg agcgggactc 1260
tgggggttca aatgaccgac caagcgacgc ccaacctgcc gaatcgtttt cggggacgcc ggctggatga 1380
ccgccgcctt ctatgaaagg ttgggcttcg atgctggagt tcttcgccc cgtagcggc gcgcggccg 1440
tcctccagcg cggggatctc agatgcgta aggagaaaat accgcacag gcgctcttc 1500
gcccgggtg aaataccgca gctgcgctcg gtcgttcggc tgccggcagc ggtatcagct 1560
gcttctcgc tcaactgact gttatccaca gaatcagggg ataacgcagg aaagaacatg 1620
caactcaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 1680
tgagcaaaag gccccctga cgagcatcac aaaaatcgac gctcaagtca gagggtggca 1740
cataggctcc gccccctga ataccaggcg tttcccccct gaagctccct cgtgcgctct 1800
aaccgcacag gactataaag taccggatcc ctgtccgctt tctcccttc ggggaagcgtg 1860
cctgttccga ccctgcccgt ctgtaggtat ctcagttcgg ttaggtcgt tcgctccaag 1920
gcgctttctc atagctcacg cccggttcag cccgaccgct ttatcgccac tggcagcagc cactggtaac 2040
ctgggtctg tgcacgaacc aagacacgac ttatcgccac tcttgaagtg gtggcctaac 2100
cgtcttgagt ccaaccgggt ttaggcgggt gctacagagt atctgcgctc tgctgaagcc agttaccttc 2160
aggattagca gagcgaggta agtatattgg ttgatccggc aaacaaacca ccgtggtag cgggtggttt 2220
tacggctaca ctagaaggac agtatattgg ttgatccggc aaacaaacca ccgtggtag cgggtggttt 2280
ggaaaaagag ttggtagctc tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 2340
tttggtttgca agcagcagat tcagtggaa ccaactcac gtaagggat tttggtcatg 2400
ttttctacgg ggtctgacgc cacttagatc cttttaaagg ccggccgcgg ccgcacatcg 2460
agattatcaa aaaggatctt tttgttaact gtttaattgtc cttgttcaag gatgctgtct 2520
cattttcttt tgcgtttttt gcctttgatg ttcagcagga agctcggcgc aaacgttgat 2580
ttgacaacag atgtttttct cctgtttgtc atatagcttg taatcacgac attgtttcct 2640
tggtttgtct cgtagaatcc gtgtgagtaa gtaagggtta catcgtagg atcaagatcc 2700
ttcgcttgag gtacagcgaa tttgttcagc ggcttgtagg ggccagttaa agaattagaa 2760
atttttaaca caaggccagt tttgttcagc ggttgtagg caatcgatc ttttgatccg 2820
acataacca gcatgtaaat atcgtaggac ttcattttaa agacgttcgc gcgttcaatt 2880
cgggagtcag tgaacaggta ccatttgccg tttcatatca cttttttcag tgtgtaatca 2940
tcactctgta ctgtgttaga tgcaatcagc ggtttcatca cttttttcag ttttttatcg 3000
tcgtttagct caatcatacc gagagcgccg tttgctaaat tgcttttgcc atagtatgct 3060
ctttgcagaa gtttttgact ttcttgacgg aagaatgatg ccattctcag ctctcagcgt atggttgctg 3120
ttgttaataa aagattcttc gccttggtag ccattctcag ctctcagcgt atggttgctg 3180
actaagtatt tgtggccttt atcttctacg tagtgaggat tttgatacgt ttttccgctc 3240
cctgagctgt agttgccttc atcgatgaac tgctgtacat tttgatacgt ttttccgctc 3300
ccgtcaaaga ttgatttata atcctctaca ccgttgatgt tgtttgccgt aatgtttacc ggagaaatca 3360
gatacgtaaa cttgtgcagt tgtcagtgtt tgtttgccgt ctgaacctga ccattcttgt 3420
gtgtagaata aacggatttt tccgtcagat gtaaatgtgg cgctgtcttt aaagacgcgg 3480
gtttggtctt ttaggataga atcatttgca tcgccaactt tttgatagaa catgtaaatc 3540
ccagcgtttt tccagctgtc aggatctccg gctaattgaa agacgatgtg gtagccgtga 3600
gatgtgtcat ccgcattttt agcgtttttg aatggccagc tgtcccaaac gtccaggcct 3660
tagtttgca agatattttt aattgtggac gaatcaaatt cagaaacttg atatttttca 3720
tttttttgct gttcagggat ttgcagcata tcatggcggt taatatggga aatgccgtat 3780
gtttccttat atggcttttg gttcgtttct ttcgcaaacg cttgagttgc caacttttt 3840
agcagtgcgg tagtaaaagt taatactgtt gcttgttttg cttctccagc cctctgtttt 3900
gttcatgtct ctttttttat gtactgtgtt gcacaataaa aaaagaccta taggtcttgc ctgctttatc agtaacaaac 4020
gaagatggca agttagtac actttgccct ttacacattt ttagactctc gtttgattg caactggtct 4080
caaagtataa actttgccct cctcatttca agaaaatcat aaaaggattt gcagactacg ggcctaaaga 4140
ccgcgcgatt tacttttcga tttgtttgat tctgtatctt ttatagtttc tgttgcattg 4200
actaaaaaat ctatctgttt ctttctatc

```

gcataaaagtt gccttttttaa tcacaattca gaaaatatca taatatctca tttcactaaa 4260  
 taatagttaa cggcaggtat atgtgatggg ttaaaaagga tcggcgggcg ctcgatttaa 4320  
 atc 4323

<210> 6

<211> 5860

<212> DNA

<213> *Corynebacterium glutamicum*

<400> 6

cccgttacca cgcgtcccag tggctgagac gcatccgcta aagccccagg aaccctgtgc 60  
 agaaagaaaa cactcctctg gctaggtaga cacagtttat aaaggtagag ttgagcgggt 120  
 aactgtcagc acgtagatcg aaagggtgcac aaagggtggc ctggctcgtac agaaatatgg 180  
 cggttcctcg cttgagagtg cggaacgcat tagaaacgtc gctgaacgga tcgttgccac 240  
 caagaaggct ggaaatgatg tcgtgggtgt ctgctccgca atgggagaca ccacgyatga 300  
 acttctagaa cttgcagcgg cagtgaatcc cgttccgcca gctcgtgaaa tggatatgct 360  
 cctgactgct ggtgagcgtg tttctaacgc tctcgtcgcc atggctattg agtcccttgg 420  
 cgcagaagcc caatcctttca cgggctctca ggctgggtgt ctcaccaccg agcgccacgg 480  
 aaacgcacgc attgttgatg tcaactccagg tcgtgtgcgt gaagcactcg atgagggcaa 540  
 gatctgcatt gttgctgggt tccagggtgt taataaagaa acccgcgatg tcaccacgtt 600  
 gggctcgtggg ggttctgaca ccactgcagt tgcgttggca gctgctttga acgctgatgt 660  
 gtgtgagatt tactcggacg ttgacgggtgt gtataccgct gacctcgca tcgttccaa 720  
 tgcacagaag ctggaaaagc tcagcttcga agaaatgctg gaacttgcgt ctgttggctc 780  
 caagattttg gtgctgcgca gtgttgaata cgctcgtgca ttcaatgtgc cacttcgcgt 840  
 acgctcgtct tatagtaatg atcccggcac tttgattgcc ggctctatgg aggatattcc 900  
 tgtggaagaa gcagtcctta ccggtgtcgc aaccgacaag tccgaagcca aagtaaccgt 960  
 tctgggtatt tccgataagc caggcgaggc tgcgaagggt ttccgtgcgt tggctgatgc 1020  
 agaaatcaac attgacatgg ttctgcagaa cgtctcttct gtagaagacg gcaccaccga 1080  
 catcaccttc acctgccctc gttccgacgg ccgcccgcgg atggagatct tgaagaagct 1140  
 tcaggttcag ggcaactgga ccaatgtgct ttacgacgac caggctcgga aagtctccct 1200  
 cgtgggtgct ggcatgaagt ctcacccagg tgttaccgca gagttcatgg aagctctgcg 1260  
 cgatgtcaac gtgaacatcg aattgatttc cacctctgag attcgtattt ccgtgctgat 1320  
 ccgatgaagat gatctggatg ctgctgcacg tgcattgcat gagcagttcc agctgggcgg 1380  
 cgaagacgaa gccgtcgttt atgcaggcac cggacgctaa agttttaaag gagtagttt 1440  
 acaatgacca ccacgcaggt tgttgggtgca accggccagg tcggccagggt tatgcccacc 1500  
 cttttggaag agcgcaattt cccagctgac actgttcgtt tctttgcttc cccacgttcc 1560  
 gcaggccgta agattgaatt cgtcgacatc gatgctcttc tgcgttaatt aacaattggg 1620  
 atcctctaga cccgggattt aaatcgctag cgggctgcta aaggaagcgg aacacgtaga 1680  
 aagccagtcg gcagaaacgg tgctgacccc ggtatgaatgt aggtacttg cagtggtt 1740  
 caagggaaaa cgcaagcgca aagagaaagc aggtacttg cagtggtt acatggcgat 1800  
 agctagactg ggcggtttta tggacagcaa gcgaaccgga attgccagct ggggcgcct 1860  
 ctggttaagg tgggaagccc tgcaaagtaa actggatggc tttcttgccg ccaaggatct 1920  
 gatggcgagc gggatcaaga tctgatcaag agacaggatg aggtactgtt cgcgatattg 1980  
 aacaagatgg attgcacgca gggtctccgg ccgcttgggt ggagaggcta ttcggctatg 2040  
 actgggcaca acagacaatc gggtgctctg atgccgcccgt gttccggctg tcagcgcagg 2100  
 ggcgcccggg tctttttgtc aagaccgacc tgtccgggtg cctgaatgaa ctgcaggacg 2160  
 aggcagcgcg gctatcgtgg ctggccacga cgggcgttcc ttgcccagct gtgctcgacg 2220  
 ttgtcactga agcgggaagg gactggctgc tattgggcga agtgcccggg caggatctcc 2280  
 tgtcatctca ccttgctcct gccgagaaaag tatccatcat ggctgatgca atgcggcggc 2340  
 tgcatacgtc tgatccggct acctgcccac tcgaccacca agcgaaacat cgcacgagc 2400  
 gagcacgtac tcggatggaa gccggtcctg tcatcagga tgatctggac gaagagcatc 2460  
 aggggctcgc gccagccgaa ctgttcgcca ggctcaaggc gcgcatgccg gacggcgagg 2520  
 atctcgtcgt gacctatggc gatgcctgct tgccgaatat catgggtgaa aatggccgct 2580  
 tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag gacatagcgt 2640  
 tggctaccgg tgatattgct gaagagcttg gcggcgaatg ggctgaccgc ctatcgctt 2700  
 tttacgggat cgccgctccc gatccgagc gcatcgctt ctatcgctt cttgaagagt 2760  
 tcttctgagc gggactctgg ggttcgaaat gaccgaccaa gcgacgcca acctgccatc 2820  
 acgagatttc gattccaccg ccgccttcta tgaaagggtt ggcttcggaa tcgttttccg 2880  
 ggacgccggc tggatgatcc tccagcgcg ggatctcatg ctggagttct tcgcccacgc 2940  
 tagcggcgcg ccggccggcc cgggtgtgaa taccgcacag atgcgtaagg agaaaatacc 3000  
 tgcacaggcg ctcttcgct tctcgtcga ctgactcgct gcgctcggtc gttcggctgc 3060

```

ggcgagcggg atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata 3120
acgcaggaaa gaacatgtga gcaaaaaggcc agcaaaaaggc caggaaccgt aaaaaggccg 3180
cggttgctggc gtttttccat aggcctccgcc cccctgacga gcatcacaaa aatcgacgct 3240
caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcggtt cccctggaa 3300
gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc 3360
tcccttcggg aagcgtggcg ggtgtgtgc acgaaccccc cgttcagccc gaccgctgcg 3480
aggctggtcg ctccaagctg cttgagtcca acccggttaag acacgactta tccgcaactg 3540
ccttatccgg taactatcgt attagcagag cgaggatgt aggcgggtgct acagagttct 3600
cagcagccac tggtaacagg ggtacacta gaaggacagt atttggtatc tgcgctctgc 3660
tgaagtgggt gcctaactac ggctacacta gtagctcttg atccggcaaa caaaccaccg 3720
tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg 3780
ctggtagcgg tgggtttttt qtttgcaagc agcagattac gcgcagaaaa aaaggatctc 3840
aagagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt 3840
aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaaggccg 3900
gccgcggccg ccatcggcct tttcttttgc gtagctctac ctgagctctt ttaaaggccg 3900
ggtcaaggat gctgtctttg acaacagatg ttttcttgcc tttgatgttc agcaggaagc 4020
tcggcgcaaa cggttgattgt ttgtctgcgt agaatcctct gttgtcata tagcttgtaa 4080
tcacgacatt gtttcctttc gottgaggta cagcgaagtg tgagtaagta aaggttacat 4140
cgttaggatc aagatccatt tttaacacaa ggccagtttt gttcagcggc ttgtatgggc 4200
cagttaaaga attagaaaca taaccaagca tgtaaatctc gtttagacgt atgccgtcaa 4260
tcgtcatttt tgatccgcgg ggtcagtgta acaggtacca tttgccgttc attttaaga 4320
cgttcgcgcg ttcaatttca tctgttactg tgtagatgc aatcagcggg ttcactactt 4380
ttttcagtggt gtaatcatcg tttagctcaa tcataccgag agcgcggtt gctaactcag 4440
ccgtgcgttt tttatcgctt tgcagaagtt tttgacttcc ttgacggaag aatgatgtgc 4500
ttttgccata gtatgctttg ttaaataaag attcttcgcc ttggtagcca tcttcagttc 4560
cagtgtttgc ttcaaatact aagtatttgt ggcttttctc ttctacgtag tgaggatctc 4620
tcagcgtatg gttgtcgctt gagctgtagt tgccttcctc gatgaactgc tgtacatttt 4680
gatacgtttt tccgtcaccg tcaaagattg atttataatc ctctacaccg ttgatgttca 4740
aagagctgtc tgatgctgat acgttaactt gtgcagttgt cagtgtttgt ttgccgtaat 4800
gtttaccgga gaaatcagtg tagaataaac ggatttttcc gtcagatgta aatgtggctg 4860
aacctgacca ttcttggtgt tggcttttta ggatagaatc atttgcatcg aatttgctgc 4920
tgtctttaa gacgcggcca gcgtttttcc agctgtcaat agaagtttgc cgcacttttt 4980
gatagaacat gtaaatacgt gtgtcatccg catttttagg atctccggct aatgcaaaga 5040
cgatgtggta gccgtgatag tttgcgacag tgccgtcagc gttttgtaat ggccagctgt 5100
cccaaagctc caggcctttt gcagaagaga tatttttaat tgtggacgaa tcaaattcag 5160
aaacttgata tttttcattt ttttgctgtt cagggatttg cagcatatca tggcgtgtaa 5220
tatgggaaat gccgtatgtt tccttatatg gcttttggtt cgtttcttcc gcaaacgctt 5280
gagttgcgcc tctgccagc agtgcggtag taaagggttaa tactgttgct tgttttgcaa 5340
actttttgat gttcatcggt catgtctcct tttttatgta ctgtgttagc ggtctgcttc 5400
ttccagccct cctgtttgaa gatggcaagt tagttacgca caataaaaaa agacctaaaa 5460
tatgtaaggg gtgacgcca agtatacact ttgcccttta cacattttag gtcttgctg 5520
ctttatcagt aacaaacccg cgcgatttac ttttcgacct cattctatta gactctcggt 5580
tggattgcaa ctggtctatt ttctcttttt gtttgataga aaatcataaa aggatttgca 5640
gactacgggc ctaaagaact aaaaaatcta tctgtttctt ttcatctctt gtatttttta 5700
tagttttctg tgcattgggca taaagttgcc tttttaatca caattcagaa aatatcataa 5760
tatctcattt cactaaataa tagtgaacgg caggtatatg tgatgggtta aaaaggatcg 5820
gcggccgctc gattttaaata tcgagaggcc tgacgtcggg 5860

```

&lt;210&gt; 7

&lt;211&gt; 38

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide

<400> 7  
cggcaccacc gacatcatct tcacctgccc tcgttccg

38

<210> 8  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide

<400> 8  
cggaacgagg gcaggtgagg atgatgtcgg tgggtgccg

38

<210> 9  
<211> 1263  
<212> DNA  
<213> Corynebacterium glutamicum

<400> 9  
gtggccctgg tcgtacagaa atatggcgggt tcctcgcttg agagtgcgga acgcattaga 60  
aacgtcgctg aacggatcgt tgccaccaag aaggctggaa atgatgtcgt gggtgtctgc 120  
tccgcaatgg gagacaccac ggatgaactt ctagaacttg cagcggcagt gaatcccgtt 180  
ccgccagctc gtgaaatgga tatgtccttg actgctgggt agcgtatttc taacgctctc 240  
gtcgccatgg ctattgagtc ccttggcgca gaagcccaat ctttcacggg ctctcagggt 300  
gggtgtgctc ccaccgagcg ccacggaaac gcacgcattg ttgatgtcac tccaggctgt 360  
gtgctggaag cactcgatga gggcaagatc tgcattgttg ctggtttcca ggggtgtaat 420  
aaagaaaccc gcgatgtcac cacgttgggt cgtgggtgggt ctgacaccac tgcagttgcg 480  
ttggcagctg ctttgaacgc tgatgtgtgt gagatttact cggacgttga cgggtgtgat 540  
accgctgacc cgcgcacgtt tcctaattgca cagaagctgg aaaagctcag cttcgaagaa 600  
atgctggaac ttgctgctgt tggctccaag attttgggtg tgcgcagtgt tgaatacgtc 660  
cgtgcattca atgtgccact tcgcgtacgc tcgtcttata gtaatgatcc cggcactttg 720  
attgccggct ctatggagga tattcctgtg gaagaageag tccttaccgg tgtcgcaacc 780  
gacaagtccg aagccaaagt aaccgttctg ggtatttccg ataagccagg cgaggctgcg 840  
aagggtttcc gtgctgtggc caccgacatc accttcacct gccctcgttc cgacggccgc 960  
tcttctgtag aagacggcac caccgacatc accttcacct gccctcgttc cgacggccgc 960  
cgcgcgatgg agatcttgaa gaagcttcag gttcagggca actggacca tgtgctttac 1020  
gacgaccagg tcggcaaagt ctccctcgtg ggtgctggca tgaagtctca cccagggtgt 1080  
accgcagagt tcatggaagc totgcgcgat gtcaacgtga acatcgaatt gatttccacc 1140  
tctgagattc gtatttccgt gctgatccgt gaagatgatc tggatgctgc tgcacgtgca 1200  
ttgcatgagc agttccagct gggcggcgaa gacgaagccg tcgtttatgc aggcaccgga 1260  
cgc 1263

<210> 10  
<211> 5860  
<212> DNA  
<213> Corynebacterium glutamicum

<400> 10  
cccgggtacca cgcgtcccag tggctgagac gcatccgcta aagccccagg aaccctgtgc 60  
agaaagaaaa cactcctctg gctaggtaga cacagtttat aaaggtagag ttgagcgggt 120  
aactgtcagc acgtagatcg aaagggtggc ctggctcgta agaaatatgg 180  
cggttcctcg cttgagagtg cggaacgcac tagaaacgtc gctgaacgga tcggtgccac 240  
caagaaggct ggaatgatg tcgtgggtgt ctgctccgca atgggagaca ccacggatga 300  
acttctagaa cttgcagcgg cagtgaatcc cgttccgcca gctcgtgaaa tggatatgct 360  
cctgactgct ggtgagcgtg tttctaaccg tctcgtccgc atggctattg agtcccttgg 420  
cgcagaagcc caatctttca cgggctctca ggctgggtgt ctcaccaccg agcggcacgg 480  
aaacgcacgc attgttgatg tcaactocagg tcgtgtgcgt gaagcactcg atgagggcaa 540  
gatctgcatt gttgctgggt tccagggtgt taataaagaa acccgcgatg tcaccacgtt 600  
gggtcgtggt ggttctgaca ccactgcagt tgcgttggca gctgctttga acgctgatgt 660  
gtgtgagatt tactcggacg ttgacgggtg gtataccgct gacccgegca tcgttcctaa 720

```

tgcacagaag ctggaaaagc tcagcttcga agaaatgctg gaacttgctg ctgttggtc 780
caagatTTTT gtgctgcgca gtgttgaata cgctcgtgca ttcaatgtgc cacttcgcgt 840
acgctcgtct tatagtaatg atccccgcac tttgattgcc ggctctatgg aggatattcc 900
tgtggaagaa gcagtcctta ccggtgtcgc aaccgacaag tccgaagcca aagtaaccgt 960
tctgggtatt tccgataagc caggcgaggc tgcgaagggt ttccgtgcgt tggctgatgc 1020
agaaatcaac attgacatgg ttctgcagaa cgtctcttct gtagaagacg gcaccaccga 1080
catcatcttc acctgccctc gttccgacgg ccgcccgcgc atggagatct tgaagaagct 1140
tcaggttcag ggcaactgga ccaatgtgct ttacgacgac caggtcggca aagtctccct 1200
cgtgggtgct ggcatgaagt ctcacccagg tgttaccgca gagttcatgg aagctctgcy 1260
cgatgtcaac gtgaacatcg aattgatttc cactctgag attcgtattt ccgtgctgat 1320
ccgtgaagat gatctggatg ctgctgcacg tgcattgcat gagcagttcc agctggcgcy 1380
cgaagacgaa gccgtcgttt atgcaggcac cggacgctaa agttttaaag gagtagtttt 1440
acaatgacca ccatcgcatg tggtgggtga acggtgaggg tccggccagg tatgcygacc 1500
cttttggaag agcgcaattt cccagrtgac actgttcgtt tctttgcttc cccacgttcc 1560
gcaggccgta agattgaatt aaatcgctag gatgctcttc tgcgttaatt aacaattggg 1620
atcctctaga cccgggattt aaatcgctag cgggctgcta aaggaagcgg aacacgtaga 1680
aagccagtcc gcagaaacgg tgctgacccc ggatgaatgt cagctactgg gctatctgga 1740
caagggaaaa cgcaagcgca aagagaaagc aggtagcttg cagtgggctt acatggcgat 1800
agctagactg ggcggtttta tggacagcaa gcgaaccgga attgccagct ggggcgcctt 1860
ctggtaaggt tgggaagccc tgcaaagtaa actggatggc tttcttgccg ccaaggatct 1920
gatggcgtag gggatcaaga tctgatcaag agacaggatg aggtatgctt cgcattgatg 1980
aacaagatgg attgcacgca ggttctccgg ggctgctctg atgcgcgcgt gttccggctg 2040
actgggcaca acagacaatc ggctgctctg tgctcgggtg cctgaatgaa ctgcaggacg 2100
ggcgcccggt tctttttgtc aagaccgacc cgggcgttcc ttgcgcagct gtgctcgacg 2160
aggcagcgcy gctatcgtag ctggccacga cgggcgttcc agtgccgggg caggatctcc 2220
ttgtcactga agcggaagg gactggctgc tattggcgga agtgccgggg caggatctcc 2280
tgcatctca ccttgctcct gccgagaaag tatccatcat ggctgatgca atgcggcgcy 2340
tgcatacgct tgatccggct acctgcccac tcgaccacca agcgaaacat cgcacgagc 2400
gagcacgtac tcggatggaa gccggctctg tcgatcagga tgatctggac gaagagcatc 2460
aggggctcgc gccagccgaa ctgttcgcga ggctcaaggc gcgcatgccc gacggcgagg 2520
atctcgtcgt gacccatggc gatgcctgct gcccgaatat catggtggaa aatggccgct 2580
tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag gacatagcgt 2640
tggtacccg tgatattgct gaagagcttg gcggcgatg ggctgaccgc ttcctcgtgc 2700
tttacggtat cgcgctccc gattcgacgc gcacgcctt ctatcgctt cttgacgagt 2760
tctctgagc gggactctgg gggtcgaaat gaccgaccaa gcgacgccc acctgcca 2820
acgagatttc gattccaccg ccgcttctta tgaaagggtg ggcttcggaa tcgtttccg 2880
ggacgcccgc tggatgatcc tccagcgcy ggatctcatg ctggagttct tcgcccagc 2940
tagcgcgcy ccggccggcc cgggtgtaaa taccgcacag atgcgtaagg agaaaaatac 3000
gcatcaggcy ctcttcgct tctcgtctca tgactcgct gcgctcggtc gttcggtgc 3060
ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata 3120
acgcaggaag gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 3180
cgttgctggc gtttttccat aggtccgcy cccctgacga gcatcaciaa aatcgacgct 3240
caagtcagag gtggcgaaac ccgacaggac tataagata ccaggcggtt cccctggaa 3300
gctccctcgt gcgctctct gttccgacct tgcgcttac cggataacct tccgcctt 3360
tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcggtgt 3420
aggtcggtcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcy 3480
ccttatccgg taactatcgt cttgagtcca acccggtagg acacgactta tcgccactgg 3540
cagcagccac tggtaacagg attagcagag cgaggatgt atttggtatc tgcyctctgc 3600
tgaagtgggt gctaactac ggctacacta gaaggacagt atccggcaaa caaaccaccg 3720
tgaagccagt taccttcgga aaaagagttg gtagctcttg agcagattac gcgcagaaaa aaaggatctc 3780
ctggtagcgg tgggtttttt gtttgcaagc agcagattac gtggaacgaa aactcacgtt 3840
aagaagatcc tttgatcttt tctacggggt ctgacgctca ctgatacctt ttaaaggccg 3900
aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac gtttaactgt aattgtcctt 3960
gccgcggccg ccatcgcat tttcttttgc gtttttattt gttgatgttc agcaggaagc 4020
gttcaaggat gctgtctttg acaacagatg ttttcttgc gtttgctata tagcttgtaa 4080
tcggcgcaaa cgttgattgt ttgtctcgt agaatcetct gtttgctata tagcttgtaa 4140
tcacgacatt gtttcttct gcttgaggt cagcgagggt tgagtaagta aaggttacat 4200
cgtaggatac aagatccatt tttaacacaa ggccagtttt gttcagcggc ttgtatgggc 4260
cagttaaaga attagaaaca taaccaagca tgtaaatac gtttagacgt atgccgtcaa 4320
tcgtcatttt tgatccgcy gagtcagtga acaggtacca tttgccgttc attttaaaga 4380
cgttcgcgcg ttcaatttca tctgttactg tgtagatgc aagcagcggt ttcacatcatt 4440

```

```

ttttcagtggt gtaatcatcg ttttagctcaa tcataccgag agcgccggtt gctaaactcag 4440
ccgtgcgttt tttatcgctt tgcagaagtt tttgactttc ttgacggaag aatgatgtgc 4500
ttttgccata gtatgctttg ttaaataaag attcttcgcc ttggtagcca tcttcagttc 4560
cagtggttgc ttcaaatact aagtatttgt ggcctttatc ttctacgtag tgaggatctc 4620
tcagcgtagt gttgtcgctt gagctgtagt tgccttcacg gatgaactgc tgtacatttt 4680
gatacggttt tccgtcacgg tcaaagattg atttataatc ctctacaccg ttgatgttca 4740
aagagctgtc tgatgctgat acgttaactt gtgcagttgt cagtggttgt ttgccgtaat 4800
gtttaccgga gaaatcagtg tagaataaac ggatttttcc gtcagatgta aatgtggctg 4860
aacctgacca ttcttggtgt tgggtctttta ggatagaatc atttgcatcg aatttgctgc 4920
tgtcttttaa gacgcggcca gcgtttttcc agctgtcaat agaagtttcg ccgacttttt 4980
gatagaacat gtaaactgat gtgtcatccg catttttagg atctccggct aatgcaaaga 5040
cgatgtggta gccgtgatag tttgcgacag tgccgtcagc gttttgtaat ggccagctgt 5100
cccaaacgtc caggcctttt gcagaagaga tatttttaat tgtggacgaa tcaaattcag 5160
aaacttgata tttttcattt ttttgctgtt cagggatttg cagcatatca tggcgtgtaa 5220
tatgggaaat gccgtatgtt tccttatatg gcttttggtt cgtttcttcc gcaaacgctt 5280
gagttgcgcc tcctgccagc agtgcggtag taaagggtta tactgttgct tgttttgcaa 5340
actttttgat gttcatcggt catgtctcct tttttatgta ctgtgttagc ggtctgcttc 5400
ttccagccct cctgtttgaa gatggcaagt tagttacgca caataaaaaa agacctaaaa 5460
tatgtaagggt gtgacgcca agtatacact ttgcccttta cacatttttag gtcttgcttg 5520
ctttatcagt aacaaacccg cgcgatttac ttttcgacct cattctatta gactctcggt 5580
tggattgcaa ctggtctatt ttctcttttt gtttgataga aaatcataaa aggatttgca 5640
gactacgggc ctaaagaact aaaaaatcta tctgtttctt ttcatctct gtatttttta 5700
tagtttctgt tgcattggca taaagttgcc tttttaatca caattcagaa aatatcataa 5760
tatctcattt cactaaataa tagtgaacgg caggtatatg tgatgggtta aaaaggatcg 5820
gcggccgctc gatttaaact tcgagaggcc tgacgtcggg 5860

```

&lt;210&gt; 11

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide

&lt;400&gt; 11

ctagctagcc attgtccttc tggcagt

27

&lt;210&gt; 12

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide

&lt;400&gt; 12

ctagtctaga cgctcgtgtt cctttaga

28

&lt;210&gt; 13

&lt;211&gt; 5720

&lt;212&gt; DNA

&lt;213&gt; Corynebacterium glutamicum

&lt;400&gt; 13

```

ggtcgactct agaggatccc cgggtaccga gctcgaattc actggccgtc gttttacaac 60
gtcgtgactg ggaataccct ggcgttacc aacttaatcg ccttgacgca catccccctt 120
tcgccagctg gcgtaatagc gaagaggccc gcaccgatcg cccttcccaa cagttgcgca 180
gcctgaatgg cgaatggcga taagctagct tcacgtgcc gcaagcactc agggcgcaag 240
ggctgctaaa ggaagcgga cactagaaa gccagtcggc agaaacggtg ctgacggggg 300

```

```

atgaatgtca gctactgggc tatctggaca agggaaaacg caagcgcaaa gagaaagcag 360
gtagcttgca gtgggcttac atggcgatag ctagactggg cggttttatg gacagcaagc 420
gaaccggaat tgccagctgg ggcgcctctt ggtaagggtg ggaagccctg caaagtaaac 480
tggaatggctt tcttgccgcc aaggatctga tggcgaggg gatcaagatc tgatcaagag 540
acaggatgag gatcgcttcg catgattgaa caagatggat tgcacgcagg ttctcgggcc 600
gcttgggtgg agaggctatt cggctatgac tgggcacaac agacaatcgg ctgctctgat 660
gccgcctgtt tccggctgtc agcgcagggg cgcgcgggtt tttttgtcaa gaccgacctg 720
tccggtgccc tgaatgaact ccaagacgag gcagcgcggc tatcgtggct ggccacgacg 780
ggcgttcctt gcgcagctgt gctcgacgtt gtcactgaag cgggaaggga ctggctgcta 840
ttgggcgaag tgccggggca ggatctcctg tcatctcacc ttgctcctgc cgagaaagta 900
tccatcatgg ctgatgcaat gcggcggttg catacgcttg atccggctac ctgcccattc 960
gaccaccaag cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggctctgtc 1020
gatcaggatg atctggacga agagcatcag ggcctcgcgc cagccgaact gttcgccagy 1080
ctcaaggcgc ggatgccga cggcgaggat ctgctcgtga cccatggcga tgcctgcttg 1140
ccgaatatca tgggtgaaaa tggccgcttt tctggattca tgcactgtgg ccggtggtg 1200
gtggcggacc gctatcagga catagcgttg gctaccctg atattgctga agagcttggc 1260
ggcgaatggg ctgaccgctt cctcgtgctt tacggtatcg ccgctcccga ttcgcagcgc 1320
atcgctttct atcgctttct tgacgagttc ttctgagcgg gactctgggg ttcgctagag 1380
gatcgatcct ttttaacca tccatatac ctgccgttca ctattattta gtgaaatgag 1440
atattatgat attttctgaa ttgtgattaa aaaggcaact ttatgccccat gcaacagaaa 1500
ctataaaaaa tacagagaat gaaaagaaac agatagattt tttagttctt taggcccgtg 1560
gtctgcaaat ccttttatga ttttctatca aacaaaagag gaaaatagac cagttgcaat 1620
ccaaacgaga gtctaataga atgaggtcga aaagtaaatc gcgcgggttt gttactgata 1680
aagcaggcaa gacctaataat gtgtaaaggg caaagtgtat actttggcgt cacccttac 1740
atattttagg tcttttttta ttgtgcgtaa ctaacttgcc atcttcaaac aggagggtg 1800
gaagaagcag accgctaaca cagtacataa aaaaggagac atgaacgatg aacatcaaaa 1860
agtttgcaaa acaagcaaca gtattaacct ttactaccgc actgctggca ggaggcgcaa 1920
ctcaagcgtt tgcgaaagaa acgaaccaa agccatataa ggaaacatac ggcatttccc 1980
atattacacg ccatgatatg ctgcaaatcc ctgaacagca aaaaaatgaa aaatatcaag 2040
tttctgaatt tgattcgtcc acaattaaaa aacgctgacg gcactgtcgc aaactatcac ggctaccaca 2160
gggacagctg gccattacaa atctctcttc tgcaaaaggc ctggacgttt 2220
tcgtctttgc attagccgga gatcctaaaa atgcggtatg cacatcgatt tacatgttct 2280
atcaaaaagt cggcgaaact tctattgaca gctggaaaaa cgctggccgc gtctttaaag 2340
acagcgacaa attcgatgca aatgattcta tcctaaaaga ccaaacacaa gaatggtcag 2400
gttcagccac atttacatqt gacggaaaaa tccgtttatt ctacactgat ttctccggtg 2460
aacattacgg caaacaacaa ctgacaactg cacaagttaa cgtatcagca tcagacagct 2520
ctttgaacat caacggtgta gaggattata aatcaatctt tgacggtgac ggaaaaacgt 2580
atcaaaatgt acagcagttc atcgatgaag gcaactacag ctgaggcgac aaccatacgc 2640
tgagagatcc tctactagta gaagataaag gccacaaata cttagtattt gaagcaaaac 2700
ctggaactga agatggctac caaggcgaag aatctttatt taacaaagca tactatggca 2760
aaagcacatc attcttcctg caagaaaagc gctctcggtg gcaaagcgat aaaaaacgca 2820
cggctgaggt agcaaacggc gctctcggtg aaacgatgat taacacactg 2880
aaaaagtgat gaaaccgctg attgcatcta acacagtaac agatgaaatt gaacgcgcga 2940
acgtctttaa aatgaacggc aaatgggtacc tgttctactg ctcccgcgga tcaaaaatga 3000
cgattgacgg cattacgtct aacgatattt acatgcttgg ttatgtttct aattctttaa 3060
ctggcccata caagccgctg aacaaaactg gccttggtgt aaaaatggat cttgatccta 3120
acgatgtaac ctttacttac tcacacttcg ctgtacctca agcgaaagga aacaatgtcg 3180
tgattacaag ctatatgaca aacagaggat tctacgcaga caaacaatca acgtttgctg 3240
cgagcttcct gctgaacatc aaaggcaaga aaactctgtg tgtcaaagac agcatccttg 3300
aacaaggaca attaacagtt aacaaataaa aacgcataag aaaatgccga tgggtaccga 3360
gcgaaatgac cgaccaagcg acgccaacc tgccatcacg agatttcgat tccaccgcg 3420
cctttatga aaggttgggc ttcggaatcg ttttcgggga cgcctcgcg gacgtgctca 3480
tagtccacga cgcccgatg tttgtagccc tggcgacgg ccagcaggtg ggccgacagg 3540
ctcatgccgg ccgcgcgcgc ctttctctca atcgctcttc gttcgtctgg aaggcagtac 3600
accttgatag gtgggctgcc cttcctggtt ggcttggttt catcagccat ccgcttgccc 3660
tcatctgtta cgcgcggcgt agcgggccag cctcgcagag caggattccc gttgagcacc 3720
gccagggtgcg aataagggac agtgaagaag gaacacccgc tcgcgggtgg gctacttca 3780
cctatcctgc ccggtgacg ccgttgata caccaaggaa agtctacacg aacccttgg 3840
caaaatcctg tatatcgtgc gaaaaaggat ggataaccg tataatgac 3900
ccgaagcagg gttatgcagc ggaaaagcgc tgcttcctg ctgttttggt gaatatctac 3960
cagtggaag caggcaaatg caggaaatta ctgaactgag ggcacaggcg agagacgatg

```



```

ccaaagagct cctgaaaatc tcgataactc aaaaaaatag cccggtagtg atcttatttc 4020
attatgggtga aagttggaac ctcttacgtg ccgatcaacg tctcattttc gccaaaagtt 4080
ggcccagggc ttcccgggat caacagggac accaggattt atttattctg cgaagtgatc 4140
ttccgtcaca ggtattttatt cggcgcaaag tgcgtcgggt gatgctgcc aactactgat 4200
ttagtgtatg atgggtgtttt tgaggtgctc cagtggcttc tgtttctatc agctcctgaa 4260
aatctcgata actcaaaaaa tacgcccggg agtgatctta tttcattatg gtgaaagttg 4320
gaacctctta cgtgccgatc aacgtctcat tttcgccaaa agttggccca gggcttcccg 4380
gtatcaacag ggacaccagg atttattttat tctgcgaagt gatcttccgt cacaggattt 4440
tattcggcgc aaagtgcgtc ggggtgatgt gccaaactac tgatttagtg tatgatgggtg 4500
tttttgaggt gctccagtggt cttctgtttc tatcagggct ggatgatcct ccagcgcggtg 4560
gatctcatgc tggagttctt cgcccacccc aaaaggatct aggtgaagat cctttttgat 4620
aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta 4680
gaaaugatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa 4740
acaaaaaac caccgctacc agcgggtggtt tgtttgccgg atcaagagct accaactctt 4800
tttccgaagg taactggctt cagcagagcg cagataccaa atactgttct tctagtgtag 4860
ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta 4920
atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca 4980
agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag 5040
cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gctatgagaa 5100
agcgccacgc ttcccgaagg gagaaaggcg gacaggatct cggttaagcgg cagggtcgga 5160
acaggagagc gcacgagga gcttccaggg ggaaacgcct ggtatcttta tagtctgtc 5220
gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc 5280
ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt 5340
gctcacatgt tctttctctg gttatccctt gattctgtgg ataaccgtat taccgccttt 5400
gagtgtagctg ataccgctcg ccgcagccga acgaccgagc gcagcgagtc agtgagcgag 5460
gaagcgggaag agcgcccaat acgcaaaccc cctctccccg cgcgttgagg gattcattaa 5520
tgcagctggc acgacaggtt tcccgaactg aaagcgggca gtgagcgcaa cgcaattaat 5580
gtgagttagc tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg 5640
ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac 5700
gccaaagcttg catgctgca 5720

```

&lt;210&gt; 14

&lt;211&gt; 6693

&lt;212&gt; DNA

&lt;213&gt; Corynebacterium glutamicum

&lt;400&gt; 14

```

accatttccg ttcattttaa gacgttcgag cgtcaatttc atctgtactg tgtagatgca 60
tcagcgggtt catcactttt ttcagtgtga atcatcggtt agctcaatca taccgagagc 120
gccgtttgct aactcaaccg tgcgtttttt atcgttttgc agaagttttt gactttcttg 180
acggaagaat gatgtgcttt tgccatagta tgctttgtta aataaagatt cttcgccttg 240
gtagccatct tcagttccag tgtttgcttc aaatactaag tatttgtggc ctttatcttc 300
tacgtagtga ggatctctca gcgtatggtt gtcgcctgag ctgtagttag cttcatcgat 360
gaactgctgt acattttgat acgtttttcc gtcaccgtca aagattgatt tataatctc 420
tacaccgttg atgttcaaag agctgtctga tgctgatacg ttaacttggt cagttgtcag 480
tgtttgtttg ccgtaatggt taccggagaa atcagtgtag aataaacgga tttttccgtc 540
agatgtaaat gtggctgaac ctgaccatct ttgtgtttgg tcttttagga tagaatcatt 600
tgcacgaat ttgtcgtgt ctttaaagac gcggccagcg tttttccagc tgtcaataga 660
agtttcgccg actttttgat agaacatgta aatcgatgtg tcatccgcat ttttaggatc 720
tccggctaata gcaaagacga tgtggtagcc gtgatagttt gcgacagtgc cgtcagcggt 780
ttgtaatggc cagctgtccc aaacgtccag gccttttgca gaagagatat ttttaattgt 840
ggacgaatca aattcagaaa cttgatattt ttcatttttt tgctgttcag ggatttgag 900
catatcatgg cgtgtaatat gggaaatgac gtatgttccc ttatatggct tttgggtcgt 960
ttctttcgca aacgcttgag ttgcgcctcc tgccagcagt gcggtagtaa aggttaatac 1020
tgttgcttgt tttgcaact ttttgatggt catcggtcat gtctcctttt ttatgtactg 1080
tgttagcggg ctgcttcttc cagccctcct gtttgaagat ggcaagttag ttacgcacaa 1140
taaaaaaga cctaaaatat gtaaggggtg acgccaaagt atacactttg ccctttacac 1200
atttttaggtc ttgcctgctt tatcagtaac aaaccgcgcg gatttacttt tcgacctcat 1260
tctattagac tctcgttggg attgcaactg gtctatcttc ctcttttgtt tgatagaaaa 1320

```

tcataaaagg	atttgcagac	tacgggccta	aagaactaaa	aaatctatct	gtttcttttc	1380
attctctgta	ttttttatag	tttctgttgc	atgggcataa	agttgccttt	ttaatcacaa	1440
ttcagaaaat	atcataatat	ctcatttcac	taaataatag	tgaacggcag	gtatatgtga	1500
tgggttaaaa	aggatcgatc	ctctagcgaa	ccccagagtc	ccgctcagaa	gaactcgtca	1560
agaaggcgat	agaaggcgat	gcgctgcgaa	tcgggagcgg	cgataccgta	aagcacgagg	1620
aagcggctag	cccattcgcc	gccaaagctct	tcagcaatat	cacgggtagc	caacgctatg	1680
tcctgatagc	ggtccgccac	accagccgg	ccacagtcga	tgaatccaga	aaagcggcca	1740
ttttccacca	tgatattcgg	caagcaggca	tcgccatggg	tcacgcagag	atcctcgccg	1800
tcgggcatcc	gcgccttgag	cctggcgaac	agttcggctg	gcgcgagccc	ctgatgctct	1860
tcgtccagat	catcctgatc	gacaagaccg	gcttccatcc	gagtacgtgc	tcgtcagatg	1920
cgatgtttcg	cttgggtggtc	gaatgggcag	gtagccggat	caagcgtatg	cagccgcgcg	1980
attgcatcag	ccatgatgaa	tagcttctcg	gcaggagcaa	ggtgagatga	caggagatcc	2040
tgcccgggca	cttcgcccac	tagcagccag	tccttccccg	cttcagtga	aacgtcgagc	2100
acagctggcg	aaggaaacgcc	cgctcgtggcc	agccacgata	gccgcgctgc	ctcgtcttgg	2160
agttcattca	gggcacugga	caggtcggtc	ttgacaaaaa	gaaccgggcg	cccctgcgct	2220
gacagccgga	acacggcgcc	atcagagcag	ccgattgtct	gttgtgcca	gtcatagccg	2280
aatagcctct	ccaccaagc	ggccggagaa	cctgcgtgca	atccatcttg	ttcaatcatg	2340
cgaaacgatc	ctcatcctgt	ctcttgatca	gatcttgatc	ccctgcgcca	tcagatcctt	2400
ggcggcaaga	aagccatcca	gtttactttg	cagggcttcc	caaccttacc	agaggcgcc	2460
ccagctggca	attccggttc	gcttgctgtc	cataaaaccg	cccagtctag	ctatcgccat	2520
gtaagcccac	tgcaagctac	ctgctttctc	cttgcgcttg	cgttttccct	tgtccagata	2580
gccagtagc	tgacattcat	ccggggtcag	caccggttct	gcggactggc	tttctacgtg	2640
ttccgcttcc	tttagcagcc	cttgccctct	gagtgccttg	ggcagcgtga	agctagccat	2700
tgtccttctg	gcagttgctt	gcgcgcctct	cgttgccacc	atctggatgc	cactgttcgg	2760
atccttctcc	gaccgcgtca	accgtgcagt	gctctacagg	atctgtgcat	ccgcaaccat	2820
cgtgctgatt	gtcccttact	acttggtcct	caacaccggc	gaaatttggg	cactgtttat	2880
cactaccgtg	attggcttcg	gcacccctct	gggtagcgtc	aacgcaatcc	tcggaaccgt	2940
catcgagaa	aacttcgcac	ctgaggtccg	ctacaccggc	gctaccctgg	gttaccaagt	3000
cggagcagca	ctcttcggcg	gtaccgcacc	cattatcgca	gcatggctgt	tcgaaatctc	3060
cggcggacaa	tggtggccaa	tcgccgtcta	cgctcgctga	tgttgccctc	tctctgtgat	3120
cgcctcgctt	ttcatccaac	gcgtcgcgca	ccaagagaac	taaaatctaa	gtaaaacccc	3180
tccgaaaggga	accacccatg	gtgaaacgtc	aactgcccaa	ccccgcagaa	ctactcgaac	3240
tcataagatt	caaaaagcca	gagctcaacg	gcaagaaacg	acgcctagac	tccgcgctca	3300
ccatctacga	cctgcgtaaa	attgctaacc	gacgcacccc	agctgcccg	ttcgactaca	3360
ccgacggcgc	agccgaggcc	gaactctcaa	tcacacgcgc	acgtgaagca	ttcgaaaaca	3420
tcgaagcgaa	ggcgtcgacc	gcaccatcgc	cattctccgc	agcgagatca	cccgcaccat	3480
ggctctcctc	ggtgtttcct	ccctcgaaga	actcgagcca	cgccacgtca	cccagctggc	3540
caagatgggt	ccagtttctg	acgcaactcg	ttctgcagcg	gcggagattt	aaaagtctct	3600
ctccttagct	attaaaaggt	gccccatcgt	ttggatgggc	accttctcgt	ttcttgcaat	3660
cggcatattc	agtcaaaaaa	tggtgaaatc	agcactttca	atttgggaca	tctactctta	3720
ggagaaaaagc	cacaaacctt	tcccacccca	caaccgtgtg	ttctgcagtc	gacccagttt	3780
agaggaaaca	tgagtgaactt	cacggaaaat	acttggactg	tccactacga	cgaagatggg	3840
gatttcccaa	aattcttcaa	ctctctaaag	gaacacgagc	gtctagagtc	gacctgcagg	3900
catgcaagct	tggcgtaatc	atggtcatag	ctgtttcctg	tgtgaaattg	ttatccgctc	3960
acaattccac	acaacatacg	agccggaagc	ataaagtgtg	aagcctgggg	tgcctaata	4020
gtgagctaac	tcacattaat	tgcgttgccg	tcactgcccg	ctttccagtc	gggaaacctg	4080
tcgtgccagc	tgcattaatg	aatcggccaa	cgcgcgggga	gaggcggttt	gcgtaattgg	4140
cgtcttcccg	cttctctcgt	cactgactcg	ctgcgtcgg	tcgttcggct	gcggcgagcg	4200
gtatcagctc	actcaaaggc	ggtaatacgg	ttatccacag	aatcagggga	taacgcagga	4260
aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaacc	gtaaaaaggc	cgcttgctg	4320
gcgtttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	ctcaagtcag	4380
aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	aagctccctc	4440
gtgcgctctc	ctgttccgac	cctgcgcgtt	accggatacc	tgtccgcctt	tctcccttcg	4500
ggaagcgtgg	cgctttctca	tagctcacgc	tgtagggtatc	tcagttcggg	gtaggtcggt	4560
cgctccaagc	tgggctgtgt	gcacgaaccc	cccggttcagc	ccgaccgctg	cgcttatcc	4620
ggttaactatc	gtcttgagtc	caacecggtg	agacacgact	tatcgccact	ggcagcagcc	4680
actggttaaca	ggattagcag	agcgagggtg	gtaggcggtg	ctacagagtt	cttgaagtgg	4740
tggcctaact	acggctacac	tagaagaaca	gtatttggtg	tctgcgctct	gctgaagcca	4800
gttaccttcg	gaaaaagagt	tggtagctct	tgatccggca	aacaaaccac	cgctggtagc	4860
ggtggttttt	ttgtttgcaa	gcagcagatt	acgcgcagaa	aaaaaggatc	tcaagaagat	4920
ctttgatct	tttctacggg	gtctgacgct	caatgggaacg	aaaactcacg	ttaagggatt	4980

```

ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttgggggtg ggcgaagaac 5040
tccagcatga gatccccgcg ctggaggatc atccagccct gatagaaaca gaagccactg 5100
gagcacctca aaaacacccat catacactaa atcagtaagt tggcagcatc acccgacgca 5160
ctttgcgccg aataaatacc tgtgacggaa gatcacttcg cagaataaat aaatcctggt 5220
gtccctgttg ataccgggaa gccctggggc aacttttggc gaaaatgaga cgttgatcgg 5280
cacgtaagag gttccaactt tcaccataat gaaataagat cactaccggg cgtatttttt 5340
gagttatcga gattttcagg agctgataga aacagaagcc actggagcac ctcaaaaaaca 5400
ccatcataca ctaaatcagt aagttggcag catcaccgca cgcacttttg gccgaataaa 5460
tacctgtgac ggaagatcac ttcgcagaat aaataaatcc tgggtgccct gttgataaccg 5520
ggaagccctg ggccaacttt tggcgaaaat gagacgttga tcggcacgta agaggttcca 5580
actttcacca taatgaaata agatcactac cgggcgtatt ttttgagtta tcgagatttt 5640
caggagctct ttggcatcgt ctctcgccgt tcccctcagt tcagtaattt cctgcatttg 5700
cctgtttcca gtcggtagat attccacaaa acaqcgagg agcagcgctt ttccgctgca 5760
taaccctgct tcggggtcat tatagcgatt ttttcggtat atccatcctt tttcgacga 5820
tatacaggat tttgccaaag ggttcgtgta gactttcctt ggtgatcca acggcgctcag 5880
ccgggcagga taggtgaagt agggccaccc gcgagcgggt gttccttctt cactgtccct 5940
tattcgacc tggcggtgct caacgggaat cctgctctgc gaggctggcc ggctaccgcc 6000
ggcgtaacag atgagggcaa gcggtggct gatgaaacca agccaaccag gaagggcagc 6060
ccacctatca aggtgtactg ccttcacgac gaacgaagag cgattgagga aaaggcggcg 6120
gcggccggca tgagcctgtc ggccctacct ctggccgtcg gccagggcta caaaatcacg 6180
ggcgctcgtg actatgagca cgtccgcgag ggcgctccgg aaaacgattc cgaagccaa 6240
cctttcatag aaggcggcgg tggaatcgaa atctcgtgat ggcagggttg gcgtcgcttg 6300
gtcggtcatt tcgctcggtc cccatcgga ttttcttttg cgtttttatt tgttaactgt 6360
taattgtcct tgttcaagga tgctgtcttt gacaacagat gttttcttgc ctttgatgtt 6420
cagcargaag ctggcgcaa acgttgattg tttgtctgcg tagaatctc tgtttgtcat 6480
atagcttgta atcacgacat tgtttcctty tcgcttgagg tacagcgaag tgtgagtaag 6540
taaraggtta catcgtagg atcaagatcc attcttaaca caaggccagt tttgttcagc 6600
ggcttgtagg ggccagttaa agaattataa acataaccaa gcatgtaaat atcgtagac 6660
gtaatgccgt caatcgctat tattgatccg cgg 6693

```

&lt;210&gt; 15

&lt;211&gt; 7561

&lt;212&gt; DNA

&lt;213&gt; Corynebacterium glutamicum

&lt;400&gt; 15

```

accatttccg ttcattttaa gaogttcgcg cgtcaatttc atctgtactg ttagatgca 60
tcagcgggtt catcactttt ttcagtgtga atcatcgttt agctcaatca taccgagagc 120
gccgtttgct aactcaaccg tgcgtttttt atcgcttttg agaagttttt gactttcttg 180
accgaagaat gatgtgcttt tgccatagta tgctttgtta aataaagatt cttcgccttg 240
gtagccatct tcagttccag tgtttgcttc aaataactaag tatttgtggc ctttatcttc 300
tacgtagtga ggatctctca gcgtatggtt gtcgctgag ctgtagtgtc cttcatcgat 360
gaactgctgt acattttgat acgtttttcc gtcaccgtca aagattgatt tataatcttc 420
tacaccgttg atgttcaaag agctgtctga tgctgatacg ttaacttggt cagttgtcag 480
tgtttggttg ccgtaatgtt taccggagaa atcagtgtag aataaacgga tttttccgtc 540
agatgtaaat gtggctgaac ctgaccattc ttgtgtttgg tcttttagga tagaatcatt 600
tgcacgaat ttgtcgctgt ctttaaagac gcggccagcg tttttccagc tgtcaataga 660
agtttcgccc actttttgat agaacatgta aatcgatgtg tcatccgcat ttttaggatc 720
tccggctaata gcaaagacga tgtggtagcc gtgatagttt gcgacagtgc cgtcagcgtt 780
ttgtaatggc cagctgtccc aaacgtccag gccttttgca gaagagatat ttttaattgt 840
ggacgaatca aattcagaaa cttgatattt ttcatttttt tgctgttcag ggatttgcag 900
catatcatgg cgtgtaatat gggaaatgcc gtatgtttcc ttatatggct tttggttcgt 960

```

```

ttctttcgca aacgcttgag ttgcgcctcc tgccagcagt gcggtagtaa aggttaatac 1020
tgttgcttgt tttgcaaact ttttgatgtt catcgttcat gtctcctttt ttatgtactg 1080
tgtagcgggt ctgcttcttc cagccctcct gtttgaagat ggcaagttag ttacgcacaa 1140
taaaaaaga cctaaaaatg gtaaggggtg acgcaaagt atacactttg ccctttacac 1200
attttaggtc ttgctgtctt tatcagtaac aaaccgcgcg gatttacttt tcgacctcat 1260
tctattagac tctcgttttg attgcaactg gtctattttc ctcttctgtt tgatagaaaa 1320

```

tcataaaagg	atttgcagac	tacgggccta	aagaactaaa	aaatctatct	gtttcttttc	1380
attctctgta	ttttttatag	tttctgttgc	atgggcataa	agttgccttt	ttaatcacia	1440
ttcagaaaa	atcataatat	ctcatttcac	taaataatag	tgaacggcag	gtatatgtga	1500
tgggttaaaa	aggatcgatc	ctctagcgaa	ccccagagtc	ccgctcagaa	gaactcgtca	1560
agaaggcgat	agaaggcgat	gcgctgcgaa	tcgggagcgg	cgaaccgta	aagcacgagg	1620
aagcggctag	cccattcgcc	gccaagctct	tcagcaatat	cacgggtagc	caacgctatg	1680
tcctgatagc	ggctccgccac	accagccggg	ccacagtcga	tgaatccaga	aaagcggcca	1740
ttttccacca	tgatattcgg	caagcaggca	tcgccatggg	tcacgacgag	atcctcgccg	1800
tcgggcatcc	gcgccttgag	cctggcgaa	agttcggctg	gcgcgagccc	ctgatgctct	1860
tcgtccagat	catcctgatc	gacaagaccg	gcttccatcc	gagtagctgc	tcgctcgatg	1920
cgatgtttcg	cttggtgggc	gaatgggcag	gtagccggat	caagcgtatg	cagccgccgc	1980
attgcatcag	ccatgatgga	tactttctcg	gcaggagcaa	ggtagagatga	caggagatcc	2040
tgccccggca	cttcgccccaa	tagcagccag	tccttcccg	cttcagtgc	aacgtcgagc	2100
acagctgcgc	aaggaaacgcc	cgctcgtggcc	agccacgata	gccgcgctgc	ctcgtcttgg	2160
agttcattca	gggcaccgga	caggctcggtc	ttgacaaaaa	gaaccggggc	cccctgcgct	2220
gacagccgga	acacggcgcc	atcagagcag	ccgattgtct	gttgtgccc	gtcatagccg	2280
aatagcctct	ccacccaagc	ggccggagaa	cctgcgtgca	atccatcttg	ttcaatcatg	2340
cgaaacgata	ctcatcctgt	ctcttgatca	gatcttgatc	ccctgcgcca	tcagatcctt	2400
ggcggcaaga	aagccatcca	gtttactttg	cagggtctcc	caaccttacc	agagggcgcc	2460
ccagctggca	attccgggttc	gcttgctgtc	cataaaaccg	cccagttctag	ctatcgccat	2520
gtaagccac	tgcaagctac	ctgctttctc	tttgcgcttg	cgttttccct	tgtccagata	2580
gcccagtagc	tgacattcat	ccggggtcag	caccgtttct	ggcgactggc	tttctacgtg	2640
ttccgcttcc	tttagcagcc	cttgccgccc	gagtgcttgc	ggcagcgtga	agctagccat	2700
tgctcttctg	gcagttgctt	gcgcgcctt	cgttgccacc	atctggatgc	cactgttcgg	2760
atccttctcc	gaccgcgtca	accgtgcagt	gctctacagg	atctgtgcat	ccgcaaccat	2820
cgtgctgatt	gtcccttact	acttggctct	caacaccggc	gaaatttggg	cactgtttat	2880

cactaccgtg	attggcttcg	gcctcctctg	gggtagcgtc	aacgcaatcc	tcggaaccgt	2940
catcgagaa	aacttcgcac	ctgaggtccg	ctacaccggc	gctaccctgg	gttaccaagt	3000
cggagcagca	ctcttcggcg	gtaccgcacc	cattatcgca	gcatggctgt	tcgaaatctc	3060
cggcggaaca	tggtggccaa	tcgccgtcta	cgctcgtgca	tggtgccttc	tctctgtgat	3120
cgctcgttcc	ttcatccaac	gcgtcgcgca	ccaagagaac	taaaatctaa	gtaaaacccc	3180
tcgaaaggga	accacccatg	gtgaaacgtc	aactgcccac	ccccgcagaa	ctactcgaac	3240
tcatgaagtt	caaaaagcca	gagctcaacg	gcaagaaacg	acgcctagac	tcgcgctca	3300
ccatctacga	cctgcgtaaa	attgctaacc	gacgcacccc	agctgccgcg	ttcgactaca	3360
ccgacggcgc	agccgaggcc	gaactctcaa	tcacacgcgc	acgtgaagca	ttcgaaaaca	3420
tcgaattcca	cccagacatc	ctcaagcctg	cagaacacgt	agacaccacc	acccaaatcc	3480
tgggcggaac	ctcctccatg	ccattcggca	ctgcaccaac	cggcttcacc	cgcctcatgc	3540
agaccgaagg	tgaaatcgca	ggtagccggag	ctgcaggcgc	tgtaggaatt	cctttcaccc	3600
tgccaccctc	gggcactacc	tccatcgaa	acgtcaaggc	caccaacccc	aacggccgaa	3660
actggttcca	gctctacgtc	atgcgcgacc	gcgaaatctc	ctacggcctc	gtcgaacgcg	3720
cagccaaagc	aggattcgac	accctgatgt	tcaccgtgga	taccccatc	gccggctacc	3780
gcacccgcga	ttcccgcaac	ggattctcca	tcgcgccaca	gctgacccca	tcacccgtgc	3840
tcaatgcaat	cccacgcccc	tggtgggtgga	tcgacttcc	gaccacccca	acccttgagt	3900
tcgcatccct	ttcctcgacc	ggcggaaacc	tgggcgacct	cctcaactcc	gcgatggatc	3960
ccaccatttc	ttacgaagac	ctcaaggtca	tcctgaaat	gtggccaggc	aagctcgtag	4020
tcaagggtgt	ccagaacggt	gaagactccg	tcaaactcct	cgaccaaggc	gtcgacggcc	4080
tcatectctc	caaccacggt	ggcgtcaac	tcgaccgcgc	accagtccca	ttccacctcc	4140
tgccacaggt	acgcaaggaa	gtcggatctg	aaaccaaccat	catgatcgac	accggcatca	4200
tgaacggcgc	cgacatcgtc	gcagccgtag	ccatgggcgc	tgacttcacc	ctcatcggtc	4260
gtgcctacct	ctacggactc	atggccggag	gcgcggaagg	cgtcgaccgc	accatcgcca	4320
ttctccgcag	cgagatcacc	cgcacatgg	ctctcctcgg	tgtttctctc	ctcgaagaac	4380
tcgagccacg	ccacgtcacc	cagctggcca	agatgggtcc	agtttctgac	gcaactcgtt	4440
ctgcagcggc	ggagatttaa	aagtttctct	ccttagctat	taaaagggtg	ccatccgttt	4500
ggatgggcac	cttctcgttt	cttgcaatcg	gcataattcag	tcaaaaaatg	ttgaaatcag	4560
cactttcaat	ttgggacatc	tactcttagg	agaaaagcca	caaaccttcc	ccacccaca	4620
accgtgtgtt	ctgcagtcga	cccagtttag	aggaacacatg	agtgacttca	cggaaaatac	4680
ttggactgtc	cactacgacg	aagatgggtga	tttcccaaaa	ttcttcaact	ctctaaagga	4740
acacgagcgt	ctagagtcga	cctgcaggca	tgcaagcttg	gcgtaatcat	ggtcatagct	4800

gtttcctgtg	tgaattgtt	atccgctcac	aattccacac	aacatacgag	ccggaagcat	4860
aaagtgtaaa	gcctggggtg	cctaattgagt	gagctaactc	acattaattg	cgttgcgctc	4920
actgcccgt	ttccagtcgg	gaaacctgtc	gtgccagctg	cattaatgaa	tcggccaacg	4980
cgcggggaga	ggcggtttgc	gtattgggcg	ctcttccgct	tcctcgctca	ctgactcgct	5040
gcgctcggtc	gttcggctgc	ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	5100
atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	gcaaaaggcc	agcaaaaggc	5160
caggaaccgt	aaaaaggccg	cgttgctggc	gtttttccat	aggctccgco	cccctgacga	5220
gcatcacaaa	aatcgacgct	caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	5280
ccaggcgtht	ccccctggaa	gctccctcgt	gcgctctcct	gttccgaccc	tgcgcgttac	5340
cggatacctg	tccgcctttc	tcccttcggg	aagcgtggcg	ctttctcata	gctcacgctg	5400
taggtatctc	agttcgggtg	aggctgthtc	ctccaagctg	ggctgtgtgc	acgaaccccc	5460
cgthtcagcc	gacgcgtcgt	ccttatccgg	taactatcgt	cttgagthca	acccggtatg	5520
acacgactta	tcgcccactgg	cagcagccac	tggtaacagg	attagcagag	cgaggthtgt	5580
aggcggtgct	acagagthct	tgaagtgggtg	gcctaactac	ggctacacta	gaagaacagt	5640
atthtggtatc	tgcgctctgc	tgaagccagt	taccttcgga	aaaagagthg	gtagctcttg	5700
atccggcaaa	caaaccaccg	ctggtagcgg	tggtthtttt	gtthtgcaagc	agcagattac	5760
gcgcagaaaa	aaaggatctc	aagaagatcc	thtgatctth	tctacggggt	ctgacgctca	5820
gtggaacgaa	aactcacgth	aagggtthtt	ggtcatgaga	thtatcaaaaa	ggatctthca	5880
ctagatcctt	thgggggtggg	cgaagaactc	cagcatgaga	tccccgcgct	ggaggthcat	5940
ccagccctga	tagaaacaga	agccactgga	gcacctcaaa	aacaccatca	tacactaaat	6000
cagthaagthg	gcagcatcac	ccgacgcact	thgcgcgcaa	thaaatacctg	tgacggaaga	6060
tcactthcgca	gaataaataa	atcctggtgt	ccctgttgat	accgggaagc	cctgggcca	6120
ctththggcga	aatgagacg	thgatcggca	cgthaagaggt	tccaactthc	accataatga	6180
aataagatca	ctaccgggcg	taththththg	gthtatcgaga	ththtcaggag	ctgathagaaa	6240
cagaagccac	tggagcacct	caaaaacacc	atcatacact	aatcagthaa	gthggcagca	6300
tcacccgacg	cactthtgcg	cgaataaata	cctgtgacgg	aagatcactt	cgcagaataa	6360
ataaatcctg	gtgtccctgt	tgataccggg	aagccctggg	ccaactththg	gcgaaaatga	6420
gacgthgatc	ggcacgthaag	aggtthcaac	thtcaccata	atgaaataag	atcactaccg	6480
ggcgththth	thgagthtatc	gagaththth	ggagctctth	ggcatcgtct	ctcgcctgtc	6540
ccctcagtht	agthaaththc	thgaththg	tgththccagt	cggtagatat	tccacaaaac	6600
agcaggggaag	cagcgctthth	ccgctgcata	accctgctth	ggggtcatta	tagcgathth	6660
thcggtatat	ccatcctthth	thgcacgata	tacaggathth	thccaaagg	thcgtgtaga	6720
ctthcctthg	thtatccaac	ggcgthcagc	gggcaggata	ggtgaagtag	gcccacccgc	6780
gagcggtgtg	thctthctth	ctgtccctth	thcgcacctg	gggtgtctca	acgggaatcc	6840
thgctctgcga	ggctggccgg	ctaccgccc	cgthaacagat	gagggcaagc	ggatggctga	6900
thgaaccaag	ccaaccagga	aggcgagccc	acctatcaag	gtgtactgcc	thccagacga	6960
acgaagagcg	attgaggaaa	aggcggcggc	ggccggcatg	agcctgtcgg	cctacctgct	7020
ggcgctcgcc	cagggtctaca	aatcacggg	cgctcgthgac	tatgagcacg	tccgcgaggg	7080
cgthcccgaa	aacgattccg	aagcccaacc	ththcatagaa	ggcggcggtg	gaatcgaaat	7140
ctcgtgatgg	caggthgggc	gtcgctthgt	cggtcathth	gctcggtacc	catcggcatt	7200
thctththg	thththththg	thtaactgtta	atthgtcctth	thcaaggatg	ctgtctththg	7260
caacagatgt	ththctthg	thtgatgtth	gcargaagct	cggcgcaaac	gthgattgtt	7320
thgtctgcgta	gaatcctctg	ththgtcatat	agctthgtaat	cacgacattg	ththctthth	7380
gctthgaggt	cagcgaggtg	thgagthaagta	araggthtaca	thgthtaggat	caagatccat	7440
ththtaacaca	aggccagthth	thgttcagcgg	ctthgtatggg	ccagthtaag	aattataaac	7500
ataaccaagc	atgthaatat	cgthtagcgt	aatgcgcgtca	atcgtcatta	thgatccg	7561

g

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**